US20060093648A1 - Hydrogels for orthopedic repair - Google Patents
Hydrogels for orthopedic repair Download PDFInfo
- Publication number
- US20060093648A1 US20060093648A1 US11/301,055 US30105505A US2006093648A1 US 20060093648 A1 US20060093648 A1 US 20060093648A1 US 30105505 A US30105505 A US 30105505A US 2006093648 A1 US2006093648 A1 US 2006093648A1
- Authority
- US
- United States
- Prior art keywords
- water
- materials
- hydrogel
- tissue
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 80
- 230000008439 repair process Effects 0.000 title claims abstract description 10
- 230000000399 orthopedic effect Effects 0.000 title abstract description 24
- 239000000178 monomer Substances 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 238000006703 hydration reaction Methods 0.000 claims abstract description 24
- 230000036571 hydration Effects 0.000 claims abstract description 22
- 238000011065 in-situ storage Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims description 160
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 68
- 238000006116 polymerization reaction Methods 0.000 claims description 37
- 230000008961 swelling Effects 0.000 claims description 32
- 230000002209 hydrophobic effect Effects 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 21
- 239000007943 implant Substances 0.000 claims description 20
- 238000004132 cross linking Methods 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000011067 equilibration Methods 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 68
- 239000000499 gel Substances 0.000 abstract description 55
- 238000009472 formulation Methods 0.000 abstract description 19
- 210000000845 cartilage Anatomy 0.000 abstract description 18
- 210000000988 bone and bone Anatomy 0.000 abstract description 9
- 230000015556 catabolic process Effects 0.000 abstract description 6
- 238000006731 degradation reaction Methods 0.000 abstract description 6
- 238000011069 regeneration method Methods 0.000 abstract description 6
- 239000004971 Cross linker Substances 0.000 abstract description 5
- 230000008929 regeneration Effects 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 210000004872 soft tissue Anatomy 0.000 abstract description 2
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 68
- 229920000642 polymer Polymers 0.000 description 37
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- MXRGSJAOLKBZLU-UHFFFAOYSA-N 3-ethenylazepan-2-one Chemical compound C=CC1CCCCNC1=O MXRGSJAOLKBZLU-UHFFFAOYSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 20
- -1 polyethylene Polymers 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 229920001577 copolymer Polymers 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- LPEKGGXMPWTOCB-UHFFFAOYSA-N methyl 2-hydroxypropionate Chemical compound COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 8
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 6
- VUIWJRYTWUGOOF-UHFFFAOYSA-N 2-ethenoxyethanol Chemical compound OCCOC=C VUIWJRYTWUGOOF-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 230000005499 meniscus Effects 0.000 description 6
- 229940057867 methyl lactate Drugs 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000001261 hydroxy acids Chemical class 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 3
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 208000035874 Excoriation Diseases 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 2
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 2
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical class CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 2
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical class CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000004222 ferrous gluconate Substances 0.000 description 2
- 235000013924 ferrous gluconate Nutrition 0.000 description 2
- 229960001645 ferrous gluconate Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical class CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- HZMYHIHXCSWJHI-UHFFFAOYSA-N 1-(1h-imidazol-2-yl)prop-2-en-1-one Chemical compound C=CC(=O)C1=NC=CN1 HZMYHIHXCSWJHI-UHFFFAOYSA-N 0.000 description 1
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical compound C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 1
- JAHSBDWGKGHCGL-UHFFFAOYSA-N 2-hydroxy-2-methyl-3-oxopent-4-enoic acid Chemical compound OC(=O)C(O)(C)C(=O)C=C JAHSBDWGKGHCGL-UHFFFAOYSA-N 0.000 description 1
- XLYWOMNZHOJENK-UHFFFAOYSA-N 2-hydroxy-2-methyl-3-oxopent-4-enoyl chloride Chemical compound ClC(=O)C(O)(C)C(=O)C=C XLYWOMNZHOJENK-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical class CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- WTVNUJRNSNVFID-UHFFFAOYSA-N 2-hydroxypropanoic acid;prop-2-enoic acid Chemical group OC(=O)C=C.CC(O)C(O)=O WTVNUJRNSNVFID-UHFFFAOYSA-N 0.000 description 1
- QENRKQYUEGJNNZ-UHFFFAOYSA-N 2-methyl-1-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound CC(C)C(S(O)(=O)=O)NC(=O)C=C QENRKQYUEGJNNZ-UHFFFAOYSA-N 0.000 description 1
- SHDZTIZBSYDZSH-UHFFFAOYSA-N 2-methylprop-2-enoyl bromide Chemical compound CC(=C)C(Br)=O SHDZTIZBSYDZSH-UHFFFAOYSA-N 0.000 description 1
- KTBQVGOFTSOVHZ-UHFFFAOYSA-N 3-(3-phenylprop-2-enoyl)pyrrolidine-2,5-dione Chemical compound C1C(=O)NC(=O)C1C(=O)C=CC1=CC=CC=C1 KTBQVGOFTSOVHZ-UHFFFAOYSA-N 0.000 description 1
- KSLINXQJWRKPET-UHFFFAOYSA-N 3-ethenyloxepan-2-one Chemical compound C=CC1CCCCOC1=O KSLINXQJWRKPET-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 229940006015 4-hydroxybutyric acid Drugs 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- IWHLYPDWHHPVAA-UHFFFAOYSA-N 6-hydroxyhexanoic acid Chemical compound OCCCCCC(O)=O IWHLYPDWHHPVAA-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002025 Pluronic® F 88 Polymers 0.000 description 1
- 229920002066 Pluronic® P 65 Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid group Chemical group C(\C(\C)=C/C)(=O)O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical class OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003903 lactic acid esters Chemical group 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- GSOZJNOMOUGFPA-UHFFFAOYSA-N n-ethenyl-n-methylprop-2-enamide Chemical compound C=CN(C)C(=O)C=C GSOZJNOMOUGFPA-UHFFFAOYSA-N 0.000 description 1
- JZAYXVPQITWZPS-UHFFFAOYSA-N n-methyl-2-methylidenebut-3-enamide Chemical compound CNC(=O)C(=C)C=C JZAYXVPQITWZPS-UHFFFAOYSA-N 0.000 description 1
- XFHJDMUEHUHAJW-UHFFFAOYSA-N n-tert-butylprop-2-enamide Chemical compound CC(C)(C)NC(=O)C=C XFHJDMUEHUHAJW-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- RBXVOQPAMPBADW-UHFFFAOYSA-N nitrous acid;phenol Chemical class ON=O.OC1=CC=CC=C1 RBXVOQPAMPBADW-UHFFFAOYSA-N 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 210000004353 tibial menisci Anatomy 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid group Chemical group C(\C(\C)=C\C)(=O)O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Definitions
- This invention is generally in the field of treatments of disease, particularly disease of skeletal or orthopedic tissues such as cartilage and bone, using polymeric materials having high adherence to tissue, low degree of swelling, toughness and biocompatibility.
- Hydrogel materials are useful in coating, sealing and adhesion of soft tissues, for example as described in U.S. Pat. No. 5,410,016 to Hubbell et al., U.S. Pat. No. 5,800,373 to Melanson et al., and U.S. Pat. Nos. 5,844,016, and 5,900,245 to Sawhney et al.
- Important properties of these hydrogels are their biocompatibility, their ability to adhere strongly to tissue, and good mechanical compliance, which is appropriately matched to that of the tissue. Biocompatibility is achieved by the use of materials that are especially compatible with tissue, such as polyalkylene oxides, and by a high water content, similar to that of the tissue being coated.
- hydrogels are not strong enough to withstand the applied stresses, particularly over the length of time required, especially for long periods of time such as those required for regeneration of bone or connective tissue. Such gels also tend to swell extensively in aqueous environments, which can interfere with mechanical properties of the injured joint or other site. Moreover, hydrogels do not tend to adhere strongly to tissue, especially to moist tissue, or when pre-formed before application to tissue. On the other hand, traditional solid implants (which typically are formed of hydrophobic materials) can be too rigid and brittle, thereby impeding or preventing tissue repair or regeneration. They may also lack lubricity, which can compromise performance in joints as well as pose a risk of abrasion of the opposing surface.
- the material includes a mixture of two components which copolymerize to form a hydrogel that contains hydrophilic and hydrophobic regions.
- the first component is covalently-crosslinkable, hydrophilic, polymeric, of high biocompatibility, and optionally spontaneously hydrolyzing (“biodegradable”). It is preferably sufficiently hydrophilic to be water-soluble at a temperature between about 0 and 70° C.
- the second component is more hydrophobic (although it is preferably water-soluble under the same conditions), is covalently polymerizable, provides structural strength and limits the water absorption capacity of the formed gel.
- the resulting polymerized hydrogel adheres tightly to the tissues, and has suitable mechanical properties, including toughness, strength and resiliency to facilitate repair or regeneration of the tissue. It also remains as a hydrogel, retaining the advantages of biocompatibility and lubricity.
- the hydrogel is optionally biodegradable.
- the material is predominantly a high-molecular weight, covalently-polymerizable macromer, which is soluble or paste-like at high concentration (e.g., 40% or more by weight) in the formulation, and which can be polymerized to form a tough, adherent, biocompatible coating on tissue.
- monomers of molecular weight less than about 1 kDa, or mixtures of monomers are the sole or principal precursors of the material.
- a significant fraction of the weight of the solution, for example 40% or more, is amphiphilic monomers; functionally hydrophobic monomers form less than about 50% of the mixture; macromers comprise from zero to less than about 30% of the weight, and water is from zero to less than about 40% of the weight.
- the polymerized materials have a controlled, low degree of swelling on continued exposure to water, combined with a tensile modulus which may be in excess of 1 MPa and also having a significant elongation to break (e.g., 10% or more).
- a tensile modulus which may be in excess of 1 MPa and also having a significant elongation to break (e.g., 10% or more).
- This combination of properties makes the materials tough, resilient, and able to withstand cyclic mechanical stress for extended periods.
- the material can also be made porous, and thereby permissive of cell or tissue ingrowth in the process of tissue repair. Porosity formation may be intrinsic to the materials or may be provided by pore-forming excipients or processes.
- FIG. 1 is a graph of the mechanical properties, tensile strength and modulus, psi, and percent elongation. These are shown for the material as initially formed, for the material after hydration (swelling) for 1 day at 37° C., and for the material after accelerated incubation for 13 days at 57° C.
- a range of materials can be used to obtain the desired hydrogel.
- the key attributes of the formed hydrogel are low swelling at high proportions of solids, high tensile modulus, significant elongation to failure, biocompatibility, and adherence, as defined below.
- SWELLING and HYDRATION Swelling results from the absorption of water by a formed polymeric material, which can be initially dry or already contain water. It is expressed herein as the percent increase in weight of a material from its initial state to a state in equilibrium with an aqueous solution, such as water or a bodily fluid. For example, if a piece of material had a weight of 1 g when formed, and 2 g after equilibration with water, it would exhibit a swelling of 100%. Direct measurement of volume could also be used to determine the degree of swelling. An appropriate time and temperature for obtaining near-equilibrium hydration of a material, in configurement relevant to implant application, is incubation for about 24 hrs in water, ideally at 37° C. to simulate body temperature.
- Prior art gels containing similar materials such as those described in U.S. Pat. No. 5,410,016 to Hubbell, et al., composed largely or entirely of crosslinked hydrophilic macromers, tend to swell several hundred percent. These gels are highly “elastic” (compliant) and correspondingly do not resist stress well. Hydrogels with relatively little swelling can be made, for example, from dilute crosslinked polyacrylamide, such as gels used for electrophoresis. However, these gels are very brittle and weak and are not suited for the purposes described herein. In these cases, the lack of swelling is achieved in part by having a low percentage of gel-forming solids in the composition. Prior art non-gel materials, such as polylactide, do not swell significantly, but have such a high modulus and hardness that they have a low elastic limit and tend to deform irreversibly or fracture under stress.
- Gels with a low degree of swelling are preferred.
- the most preferred gels have an equilibrium swelling of about 150% or less.
- Preferred gels have a swelling of about 200% or less.
- Gels with swelling below about 300% are potentially of use.
- Low degrees of swelling are achieved at high concentrations of gel-forming solids.
- Suitable ranges of gel-forming solids at the time of gel formation are at least about 30% by weight, preferably over 40%, more preferably over 50%, and yet more preferably over 60%.
- the preferred embodiments have over 70% solids at the time of formation.
- the concentration of solids after equilibrium swelling is also high.
- the gel-forming materials should comprise at least 20% by weight of the gel after swelling to equilibrium in bodily fluids. Higher values are preferable, such as 30% or more.
- the preferred embodiments have 40% or higher solids after equilibration with water.
- a material's modulus is the ratio of stress (applied force per unit area) over strain (ratio of compressed or stretched length to original length). It is expressed in units of force per unit area, such as Pascals or PSI, and is typically measured quantitatively on a device such as an Instron® mechanical tester.
- the gels described herein have a modulus that is quite high for a hydrogel. The most preferred values of the tensile or compressive modulus, at small strains and after swelling, are over 1 megaPascal (MPa). Gels with a post-swelling modulus of 500 kiloPascals (kPa) or greater are preferred. Gels with a modulus of 100 kPa, preferably 200 kPa or more, are of use in the invention. Gels with a modulus above about 50 kPa can be used in low-stress situations.
- elongation to failure is the strain (degree of deformation) at which the material fails (breaks), expressed as a percent of the material's original length. It is also measured on an Instron® tester or similar device. A material with a 100% elongation (strain) at failure is double its original length. Materials with a significant elongation to failure are preferred. Preferred materials have values above about 300%, and suitable materials can have values in the range of about 25% to over 800% if other properties are appropriate. In addition to the elongation to failure value, having a measurable range in which the material is elastic, i.e., returns to its original shape, is important for its durability, particularly under the conditions found in joints and other orthopedic tissues.
- the term “elastic” includes “substantially elastic” and “predominantly elastic” and is used to describe materials that have low modulus in tension or compression and high elongation to break.
- Substantially elastic materials include materials in which up to 25% of the deformation can be irreversible (plastic) deformation. The deformation of preferred materials is substantially elastic.
- TOUGHNESS The values of elongation and modulus can be combined to give a quantitative measurement of toughness, which is the area under the stress-strain curve to the failure point.
- toughness is used herein only in a comparative sense unless otherwise specified.
- a qualitative measure of toughness, for gels of a particular thickness, is obtained by compressing a piece of gel between the jaws of a locking surgical hemostat.
- a standard compressive load can be achieved by specifying how many “clicks”—detents giving progressively higher compressive force—on the locking mechanism are used. Gels that do not fracture in this test are tougher than those that do fracture.
- BIOCOMPATIBILITY A material is biocompatible if its implantation does not provoke a severe local or systemic inflammatory reaction. This is in distinction to the transient mild inflammatory response that accompanies essentially all implants. Biocompatibility may be determined by histological examination of the implant site at various times after implantation. One sign of poor biocompatibility can be a severe, chronic, unresolved phagocytic response at the site. Another sign of poor biocompatibility can be necrosis or regression of tissue at the site.
- ADHERENCE Adherence of gels to tissue can be optimized by techniques that employ functional primers, as described in U.S. Pat. No. 5,800,373 to Melanson et al., U.S. Pat. Nos. 5,844,016, or 5,900,245 to Sawhney et al. for gels formed by polymerization of ethylenically unsaturated precursors. Suitable gel compositions form strong bonds to tissue. These techniques are also applicable to creating strong adherence of the materials to tissue, including tissue to which it is difficult to obtain adherence by conventional methods, for example, cartilage.
- a general procedure for applying materials to orthopedic tissue involves brushing or dabbing primer over a larger area than that over which the material is applied. Thereafter, material is brushed or dabbed over the deposited primer. Then bulk material is applied by dripping (if liquid) or spreading (if paste) over yet a smaller area of the treated zone. Then light (at appropriate wavelength, intensity, distance and for an appropriate time) is applied at each zone, or other means of polymerizing the material are used.
- Adherence of the hydrogel to tissue may be determined by passing a 20 gauge needle through the base of the hydrogel near the tissue interface, then grasping the needle at both ends, and finally lifting the needle parallel to the tissue while holding down the test object.
- the needle eventually releases either via adhesive failure of the hydrogel to the tissue, or by cohesive failure of the hydrogel or tissue.
- the examples below show many primed hydrogels that provided bonds strong enough to cause cohesive failure.
- Adherence may be qualitatively rated as follows. “Excellent adherence” means that upon application of force to the needle, cohesive failure of tissue or gel was observed. “Moderate adherence” means that upon application of force to the needle failure was partially cohesive and partially adhesive. “Fair adherence” means that the mode of failure was adhesive failure. “Poor adherence” means that a light force, as compared with the force needed to cause cohesive failure, was needed to cause adhesive failure. Preferred gels have moderate to excellent adherence on this scale.
- LUBRICITY is the quality of a surface that confers relatively low frictional forces between that surface and an opposing surface, often via a thin film of liquid material on the surface that wets both surfaces.
- the fluid can be adsorbed to the surface, or exuded by the surface, or both.
- Hydrogels tend to be naturally lubricious.
- hydrogel surfaces have an innate affinity for water.
- Natural cartilage has a similar property.
- Gel or hydrogel includes the traditional hydrogel, in which polymer and water each form continuous phases. As used herein, these terms may also include materials absorbing at least 5% of an aqueous phase, which is not necessarily continuous.
- “functionally hydrophobic monomers” means monomers including reactive groups and hydrophobic groups and having up to one group that is no more hydrophilic than an alkyl ester or a dialkyl amide. Examples of functionally hydrophobic monomers include vinyl caprolactam (VC), methyl acrylate, methyl methacrylate, styrene, N-vinyl pyrrolidone (VP), and N-vinyl imidazole (VI). In contrast, examples of amphiphilic monomers include diacetone acrylamide (DAA), vinyloxyethanol (VOE), 2-acrylamido-2-methylpropane (AMPS), and methyl acryloyl lactate (ALM) and its relatives.
- DAA diacetone acrylamide
- VOE vinyloxyethanol
- AMPS 2-acryl
- the gel-forming materials comprise reactive polymers (macromers), with molecular weights ranging from about 500 Daltons (Da) to about 200,000 Da, measured by any conventional technique. These macromers contain hydrophobic and hydrophilic regions and are combined, in most embodiments, with reactive low molecular weight monomers, having molecular weights below about 1000 Da.
- the combination is preferably characterized by being sufficiently hydrophobic after polymerization to provide hydrogels with low swelling and relatively high solids content after equilibration with water.
- the preferred polymeric solids concentration after equilibration of the formed gel with water or bodily fluids will be in the range of from about 15% wt/wt to above 70% wt/wt. This characteristic may involve phase separation or coacervate formation during polymerization, leading to a heterogeneous hydrogel.
- Some products may be porous.
- Macromers which polymerize to form hydrogels via condensation or electrophile/nucleophile chemistry are described in numerous publications, including U.S. Pat. Nos. 5,744,545, 5,614,587, and 5,874,500 to Rhee et al; U.S. Pat. No. 5,514,379 to Weissleder and Bogdanov; U.S. Pat. No. 5,173,301 to Itoh and Matsuda; U.S. Pat. No. 5,583,114 to Barrows et al, and U.S. Pat. No. 4,057,535 to Lipatova et al. Other examples include U.S. Pat. No. 4,839,345 to Doi, et al.; U.S. Pat.
- poly(ethylene glycol) (PEG) is preferred for forming the macromeric backbone because of its biocompatibility and stability
- other macromolecules are also useful. These include, as illustrated below, PEG-PPO (copolymers of polyethylene glycol and polypropylene oxide), hydrophilic segmented urethanes, and multivalently-derivatizable surfactants, in each case derivatized to carry reactive groups.
- PEG-PPO copolymers of polyethylene glycol and polypropylene oxide
- hydrophilic segmented urethanes hydrophilic segmented urethanes
- multivalently-derivatizable surfactants in each case derivatized to carry reactive groups.
- hydrophilic natural and synthetic polymers are suitable for use in backbones for forming macromers to make the bydrogels.
- hydrophilic synthetic polymers such as polyvinylpyrrolidone, polyvinyl alcohol (including partially deacetylated polyvinylacetate), poly[meth]acrylic acid and poly[meth]acrylamides (where “[meth]” indicates optional methyl substitution of the acrylate group), and mixed water-soluble copolymers such as copolymers of maleic acid and ethylene.
- Natural, synthetic and semi-synthetic saccharides and polysaccharides include hydroxyalkyl celluloses, dextran, FicollTM, bacterial fermentation products such as xanthan or gellan, and food-grade materials such as alginates, carrageenans, pectins, agars, glucomannans, galactomannans, hyaluronic acid, heparin, chondroitin sulfate, and other glycosaminoglycans, and starch. Proteins and nucleic acids can be used.
- Multivalently-substitutable lipids such as “dimer fatty acid”, monoacylglycerol, phosphatidyl inositol, cardiolipin, and derivatives thereof, can also be used as components of a backbone for forming a macromer.
- systems containing only macromeric components can be used. It is important in this case that at least some of the macromeric components have significant hydrophobic character, to form hydrophobic domains on polymerization.
- Suitable backbones for such a macromer, to which polymerizable groups can be grafted include water-soluble or water-dispersible copolymers of ethylene oxide with propylene oxide and/or butylene oxide, and polyurethanes, polyesters and polyamides containing hydrophilic segments.
- Low molecular weight monomers that are useful in the hydrogel materials share several key properties.
- the first property is that the monomers should react appropriately in the presence of the other components of the system, in particular a macromeric component or water, when either or both are present. To obtain this property, it is preferable, but not required, that the monomers be miscible with other components of the material.
- One key material is water at room or elevated temperature, up to about 100° C., with which the monomer is preferably soluble or miscible to a significant extent, such as 30% wt/vol., preferably 40% wt/vol., and most preferably 50% wt/vol. or higher.
- the monomer can dissolve in or be a solvent for a macromer under similar conditions, in the presence or the absence of water.
- compositions formed of partially immiscible macromers and monomers can be suitable if the polymerization reaction gives the required properties for the final polymerized materials.
- the second property is that the monomer should impart the characteristic of low swelling in aqueous solution to the hydrogel upon polymerization.
- One mechanism for providing decreased swelling is a significant decrease in water absorption of a polymer formed predominantly from the monomer by polymerization.
- a distinctly heterogeneous hydrogel may form upon polymerization, or during subsequent swelling in aqueous solutions.
- the product formed from the polymerization of the monomer and the macromer must contain water, or must be capable of absorbing water. This can be as little as 2% to 5% by weight at equilibrium, but preferably is at least 10% and more preferably is 20% or more. This water is important for providing lubricity to the polymerized composition.
- the material does not need to be a hydrogel at the conclusion of polymerization, if it can absorb or adsorb sufficient water to become lubricious when in contact with bodily fluids.
- Unsaturated monomers which have been found experimentally to be preferable for this function include diacetone acrylamide (“DAA”; CAS 2873-97-4).
- DAA diacetone acrylamide
- the minimum effective concentration for DAA is about 30% as sole monomer, but may be less in blends with other monomers.
- These include vinylcaprolactan (VC), vinyloxyethanol (VOE), or up to about 10% of 2-acrylamido 2-methyl propanesulfonic acid (AMPS). It is believed that other low molecular weight monomers are suitable when blended with DAA; suitability and limiting concentrations are readily determined by experimentation.
- the useful range of monomers increases substantially when the macromer has significant hydrophobic segments or domains.
- the effectiveness of the preferred low molecular weight monomers is due to a balance of hydrophobic and hydrophilic domains or segments, in the composition after polymerization.
- the hydrophobic domains serve to control and limit water uptake, and reinforce the polymerized composition which functions as a water-swollen matrix. This is why it is important that at least some of the macromer, or a segment of the macromer, is hydrophilic, and remains hydrophilic after the polymerization; and that a segment of the macromer, or of the monomer after polymerization, be hydrophobic.
- a representative class of preferred monomers are acryloyllactic acid-methyl esters (ALM).
- Methyl acryloyl lactate; the acrylic ester of lactic acid methyl ester; CH 2 ⁇ CH—C( ⁇ O)OCH(CH 3 )C( ⁇ O)OCH 3 ) is prepared as described in Example 30.
- the ALM monomer can be viewed as being composed of three parts, generally designated “AHK”.
- A designates a reactive group, which in ALM is the residue of acrylic acid after esterification to the hydroxy group of lactic acid.
- “H” designates a hydroxy carboxylic acid, which is lactic acid in ALM.
- K designates an alkyl group, or another relatively inert group, containing an alcohol group before esterification to the H carboxyl group.
- the K group is the residue of methanol.
- ALM structure can readily be manufactured, and will allow the tailoring of the properties of the monomer to a particular tissue situation.
- each of these groups can be replaced with analogous groups of the same class, resulting in variations in the hydrophobicity, crystallinity, and hydrolysis stability of the materials resulting from the polymerization of these monomers.
- A can be selected from acrylic acid and methacrylic acid, or from other acids carrying unsaturation.
- crotonic, isocrotonic, tiglic, angelic, and cinnamic acids include crotonic, isocrotonic, tiglic, angelic, and cinnamic acids, and unsaturated diacids including maleic, fumaric, citraconic, mesaconic, itaconic, citric and isocitric acids, as well as monoesters or monoamides of the dicarboxylic acids.
- H can be any of a large number of hydroxy carboxylic acids. These are the residues widely used to create degradability in polymers, so that they will degrade to small, metabolizable or excretable units, in a reasonably predictable way in the body. The most commonly used of these are the lower alkyl hydroxy acids, including glycolic acid, lactic acid, 3-hydroxy-propanoic acid, 2-, 3-, or 4-hydroxybutyric acid, the various isomers of hydroxypentanoic acid (including valeric acid), and the hydroxyhexanoic acid isomers, including 2-caproic acid and 6-caproic acid (epsilon-caproic acid).
- hydroxy acids are available in “lactide” or lactone forms, which can simplify synthesis.
- Other commonly used hydroxy acids include the lactone and hydrolyzed forms of dioxanone (1,4-dioxan-2-one) and other cyclic dioxanones, and of similar 1-oxan-2-one ethers with 5 and 7 membered rings.
- H when H is formed from the 2-hydroxy acids, the monomers and the corresponding polymers and copolymers tend to degrade by hydrolysis most rapidly, followed by the 3-, 4-, 5-, and 6-hydroxyacids. This is due mainly to the hydrophobicity of the higher hydroxy acids. Hydrophobicity tends to exclude water from the labile ester bond between the H and the K group, which slows degradation. Hydrophobicity can also be affected by increasing the hydrocarbon content of the hydroxy acid by incorporation of side chains, such as the methyl group in lactic acid. Likewise, increased hydrophobicity of the K group also slows hydrolysis. Steric protection of the ester linkage from water would also slow hydrolysis.
- Degradation time is also affected by the crystallinity of the polymer or copolymer. Increases in crystallinity tend to exclude water from the labile ester bond between the H and the K group, which slows degradation. Crystallinity of the polymer or copolymer can be affected by typical factors such as tacticity, molecular weight, etc.
- H can be the residue of an amino acid, especially of an alpha-amino acid.
- the linkage between the A and the H group is then an amide linkage. This increases the difference in hydrolysis rates between the A-H linkage and the H-K linkage when K is being removed.
- glycine ethyl ester hydrochloride is commercially available, and could be acrylated under essentially the same conditions as methyl glycolate (above), particularly after conversion to the free amine. It is expected that it would preferentially de-esterify to form the derivatized lactic acid under the same conditions as ALM (see Example 33).
- K is an esterified group, which is methyl in ALM.
- the lower alcohols are preferred as sources of K groups, as they will become innocuous alcohols upon hydrolysis of the ester bond to the H group's carboxyl. These include methanol, ethanol, propanol, isopropanol, isomers of butanol, isomers of pentanol, and isomers of hexanol. More generally, larger alkyls are also suitable, such as those formed from fatty acids (containing up to about 30 carbon atoms), or from sterols (e.g., cholesterol, cholestanol) or other lipid materials with hydroxy groups (e.g., sphingosine). As is known, increase in the size of the K component will tend to increase the hydrophobicity of the material, which will change both its mechanical properties and its degradation time.
- K groups containing alcohol groups are possible. These may include biologically active molecules, polymers, and other large molecules. Steric considerations will generally require that such monomers be polymerized together with small monomers—for example, AHK molecules with K derived from lower alcohols; or suitable non-AHK polymerizable monomers.
- HK materials for the synthesis in which an activated “A” group (here, acryloyl chloride) is added to a preformed HK group (here, methyl lactate) are commercially available. These include ethyl and/or methyl esters of lactic, glycolic, 2-hydroxybutyric, 2-hydroxycaproic, and 6-hydroxycaproic acid. However, propyl and higher substituents are not readily available.
- the amine equivalents e.g., glycine ethyl ester hydrochloride
- a synthetic method for making monomers containing any of a wide range of K groups is described in the examples. The principal requirement of the “K” group is that it contain at least one hydroxyl group.
- compositions can also include ancillary reagents, such as catalysts or initiators of polymerization; excipients, including buffers; stabilizers; and dye.
- ancillary reagents such as catalysts or initiators of polymerization
- excipients including buffers; stabilizers; and dye.
- the compositions will be tailored to accommodate the chemistry or chemistries that are used to polymerize and crosslink the materials.
- the hydrogel materials may contain other therapeutic, prophylactic or diagnostic materials which interact with or on the tissues to which the material has been applied. These materials include drugs and other therapeutically active materials, such as proteins, small molecule drugs, nucleic acid molecules, sugars and polysaccharides, lipids, natural extracts, glycosaminoglycans and inorganic compounds. As noted above, excipients such as plasticizers, emollients, fillers, lubricants, buffers, and stabilizers, may also be added. Any of these may be admixed into the material before or during polymerization or crosslinking, and optionally may be encased in liposomes, microparticles, or other delivery forms, for local or systemic delivery.
- drugs and other therapeutically active materials such as proteins, small molecule drugs, nucleic acid molecules, sugars and polysaccharides, lipids, natural extracts, glycosaminoglycans and inorganic compounds.
- excipients such as plasticizers,
- reaction chemistry that is compatible with application in an aqueous environment, and that can be conducted safely on living tissue, is potentially suitable to polymerize the gels.
- a preferred chemistry involves the use of ethylenically-unsaturated materials, including but not limited to vinyl, acrylic, and alkyl groups (“unsaturated group”). At least some of the macromer or the monomer is preferably substituted (,as terminal or side groups,) so as to be at least difunctional to allow crosslinking in addition to linear polymerization.
- Reactions with ethylenically unsaturated materials commonly are free-radical chain-growth reactions, and typically are initiated with the use of a chemical initiator or a photoinitiator.
- Free-radical polymerizable linkages are preferred for forming the hydrogels.
- the preferred monomers, DAA and ALM react by this mechanism, and it is convenient to use the same method for crosslinking.
- polymerization and/or crosslinking can be provided by other chemistries, such as those noted above. Any crosslinking or polymerization method that can be used in situ in the body is potentially of use.
- An alternative chemistry involves step-growth (condensation) polymerization, and similar heterolytic reactions.
- a leaving group such as an N-hydroxy succinimide ester
- a nucleophilic group such as an amine.
- the preponderance of reactive molecules must have a functionality of two.
- the composition must contain reactive molecules with functionality greater than two. Because polymerization of at least one component to form a low-solubility material is thought to be involved in obtaining the preferred gel compositions, there may be several types of reactive materials in the composition.
- one component, or a fraction of a component could carry an electrophilic center with a good leaving group as well as an unsaturated group, while another reactive component could carry nucleophilic groups. Then the first component could polymerize by free radicals, while also becoming crosslinked by the second component.
- certain reactive groups are inherently capable of undergoing several types of crosslinking. For example, a maleimide group can undergo Michael-type addition with a nucleophile such as an amine or thiol, but can also polymerize by free radical polymerization of its double bond. It can also react by hydrolysis of its strained ring, for example by reaction with an amine to form an amide.
- Hydrogels can be homo-polymers or hetero-polymers (or co-polymers), interpenetrating networks or semi-interpenetrating networks.
- the polymerized materials can be covalently or non-covalently crosslinked.
- Non-covalently crosslinked materials have a molecular weight after polymerization of less than 200 kDa.
- hydrogels described herein are useful in the treatment of what may be termed “orthopedic tissues”.
- the medical specialty of orthopedics is concerned with the preservation, restoration and development of the form and function of the musculoskeletal system, extremities, spine and associated structures by medical, surgical and physical methods.” (Stedman's Medical Dictionary, 25 th ed., Williams & Wilkins, 1996).
- Orthopedic tissues include bone, cartilage, and related structures, for example, meniscus, bursa, synovial membranes, and other structures of the joints, as well as tendons, ligaments, muscles and the annulus and nucleus of the vertebral disks. Tissues with similar mechanical properties such as teeth, gums, and gingival ligaments can also be treated effectively with the hydrogel materials.
- hydrogel forming reagents have been tailored to enable the creation of materials that are hydrogels (as herein defined), and that also adhere well to orthopedic tissues. Such strong adherence can be difficult to achieve with polymeric materials in current uses. For example, fasteners and sculpting of undercuts and hollows in bone and cartilage can be required to obtain good attachment of available polymeric implants.
- the hydrogel materials described herein are characterized by their strong adherence. When polymerized in the presence of the tissue with the use of appropriate priming techniques, the hydrogels can adhere to tissue with sufficient tenacity that either the gel or the tissue will fail before the adhesive bond between the tissue and the implant is broken (“excellent” adherence, as defined above). “Good” adherence is also acceptable in these materials.
- these materials have the appropriate mechanical strength and other mechanical properties, such as resilience and stiffness, to withstand the forces applied in these anatomical situations.
- the same physical properties make the hydrogels suitable for coating of implants applied to the joints and similar structures.
- the hydrogel coating can simulate the natural lubricity of an orthopedic surface, such as cartilage, thereby allowing favorable joint articulation while preventing damage as the underlying tissue heals.
- Another benefit is the ability to remodel a joint surface by shaping the polymerized deposit with a mold to create or re-create a surface profile of a tissue, such as a condyle.
- a desired profile can be present in a transparent or highly translucent molding member.
- the tissue surface is primed with reactive materials as described herein, and the cavity of the mold is filled with materials to form the hydrogel.
- the filled mold is placed, or is subsequently applied to the tissue surface, so that the unpolymerized materials are in contact with the primed surface. Then the material is polymerized by application of light, or by waiting for polymerization of pre-mixed reactive materials (in which latter case, the mold need not be transparent or translucent).
- the mold After polymerization, the mold is removed, leaving a dense, lubricious, tightly-adhering hydrogel-forming material having the appropriate profile.
- the material is applied as a paste, or physically gels on contact with tissue (for example, because of a temperature change), then it can be shaped to a profile using a scalpel or other instrument before or after polymerization.
- the hydrogel materials and techniques described herein can be used to resurface damaged sites.
- the site from which cartilage grafts is taken can be irregular, and be susceptible to damage, or can damage opposing surfaces. Coating or filling the void with the hydrogel materials will prevent ancillary damage while the tissue heals.
- the material may optionally be designed to be removed by spontaneous degradation, or by controlled abrasion, during this process.
- a particular advantage of the hydrogel materials, in this and other uses, is that the improved materials can be applied by minimally invasive techniques, for example through a needle or narrow cannula, and polymerized in situ. This makes resurfacing and other operations simpler, and thus less traumatic and less costly, while improving the chances of success.
- the application procedure is simple and minimally invasive, it can be repeated as required to maintain the usefulness of a tissue—for example, a knee joint—and thereby postpone the requirement for a joint replacement or other invasive repair procedure.
- the material can concurrently degrade by simple or enzymatically-catalyzed hydrolysis.
- a torn area of a meniscus can be initially repaired by standard methods, which use pinning and suturing to re-appose the torn segments. A layer of the hydrogel is then applied. The firmly-adherent gel material redistributes the applied load on the meniscus during healing. Similar uses can be found in other locations in the body, such as in the spine, and in non-limb joints, such as the jaw.
- hydrogel materials have been described in terms of coatings on tissue or on implants, it is also possible to use these materials as extremely strong yet biocompatible medical adhesives, by coating both surfaces to be adhered with a primer and polymerizing the materials while the materials are in contact with both primed surfaces. Allowance should be made for the predictable expansion of the adhesive during its hydration to equilibrium.
- the examples demonstrate that it is possible to make extremely strong, resilient, low-swelling hydrogels which are biocompatible and which adhere well to orthopedic tissue.
- the examples also show that the more successful formulations, in terms of having the desired end properties as polymerized gels, have an initial water content before polymerization ranging from 0% up to about 40% (wt/wt). The range giving the best gels was broad: successful formulations were found at 0% and at 33%, and at several concentrations in between.
- Macromers having molecular weights above 500 Da typically over 1000 Da, and as high as about 100 kDa, constituted from 0% to about 50% of the weight The range of about 10% to about 20% was most often successful.
- the macromers used were also crosslinking agents. It is believed that the macromers serve two functions, as the crosslinker and as the hydrophilic region, and that these functions could be placed in separate molecules if required. However, the combination of the two functions in one molecule is convenient.
- Monomers with molecular weights below 1000 Da, and more typically below about 500 Da, constituted from about 45% up to 100% of the formulation, typically in the range of about 50% to 90%, and most frequently in the range of about 60 to 80%.
- the most successful monomers, DAA and ALM each have hydrophobic groups and more than one hydrophilic group.
- ALM has two ester bonds, while DAA has an amide and a ketone.
- the poorly water-soluble ALM could form gels at 100% concentration, which absorbed over 2% of water, and formed better gels when containing a hydrophilic crosslinker.
- the water-soluble DAA, VC or combinations of the two, without a crosslinker were not suitable as the sole polymerizable component.
- polyacrylamide and polyacrylic acid are not suitable as major components of the gel since they are known to swell and form weak gels. It is significant that DAA is amphiphilic, having both hydrophilic and hydrophobic regions, and it is believed that a substantial proportion of the materials in the hydrogel should be amphiphilic.
- very hydrophobic monomers such as methyl methacrylate or styrene, form rigid, non-swelling polymers. It is clear from the examples concerning pure ALM that using ALM as the sole monomer produces materials near the low end of the range for water absorption. However, addition of more hydrophilic monomers, particularly crosslinking macromers, imparts an improved degree of hydration as well as improved resiliance.
- a preferred composition includes at least about 5%, preferably about 10%, and most preferably about 20% to at least about 50%, of a monomer or macromer having substantial water solubility.
- the hydrophilicity can be provided by an amphiphilic macromer, even one of low solubility (e.g., certain poloxamers, such as Pluroric-type polymers) having a substantially water-soluble block comprising at least about 20% of the weight of the polymer.
- compositions that are most suitable for these applications form gels that have a maximum equilibrium swelling in water of about 300%, and preferably less than 200%. Values of about 100%, or less, are more preferred.
- percent of solids in the swollen state should be at least about 20%, preferably 30%, and most preferably 40% or more.
- a pre-swelling solids content of 40% or more of polymerizable materials is preferred, but this value is secondary to obtaining the required post-swelling values.
- the gels both before and after swelling must be resilient, for durability under dynamic conditions of use.
- a value of the percent elongation to failure of 100% or more is preferred, but smaller elongations, such as 25% to 50%, can be suitable, especially at high solids contents.
- Tensile strength and modulus are clearly important. It is straightforward to obtain a measurement of tensile values, but not as easy to prescribe a limiting value, in part because of the non-criticality of the exact form of the stress-strain curve, in this application.
- the preferred materials have tensile values of well over 1 MPa before hydration, and of over 0.4 MPa after hydration. Post-hydration values can clearly be lower, especially when the implant or coating is subject to compressive loading with little shear. Post-hydration values of 100-200 kPa are suitable. In some uses, tensile strengths of 20 to 50 kPA
- a macromer consisting of a 35 kiloDalton (kDa) core (manufacturer-specified molecular weight; MW about 27 kDa by GPC) of polyethylene glycol (PEG) is reacted with trimethylene carbonate, giving hydroxy-terminated molecules with an average of about two PEG segments and about 15 TMC groups per molecule.
- PEG polyethylene glycol
- This molecule is then end-capped with acryloyl chloride to make it crosslinkable.
- the molecule is called 35KTA2. Details of synthesis are described in WO 98/12243 by Focal.
- a solution was prepared in water which contained by weight about 68% DAA, 15% 35KTA2, about 17% water, and materials for redox-assisted photopolymerization, including Irgacure® 651 (2,2-dimethoxy 2-phenyl acetophenone; DMAP), t-butyl hydroperoxide, and tiethylamine as electron carrier and buffer. This was accomplished by adding 3.0 g of 35kTA2 and 13.6 g of DAA to 3.4 g of water, and heating to 70° C. with stirring to complete dissolution. Then 83 microliters of 6% t-butylhydroperoxide (in water) and 30 microliters of molten DMAP were added, with stirring and heating as required for dissolution. The mixture was treated by centrifugation or standing to remove bubbles. It was either stored at minus 40° C. (dark), or used warm (45-50° C.) or at room temperature to form a hydrogel.
- Irgacure® 651 2,2-d
- This gel-forming material was polymerized by illumination with near-UV light, 350-400 nm band from a xenon source, for about 40 seconds at about 50 to 100 mW per square centimeter, to form bulk gels for testing of mechanical and other properties.
- the tissue was primed with a solution prepared as follows. Ferrous gluconate (0.71 g) and 1.42 g D-fructose were dissolved in 100 mL of water. In 7.0 g of this solution, 3.0 g of a low-molecular weight macromer, 3.3 KLA2 (made from nominal 3.3 kDa PEG with an average of five lactate residues per PEG, acrylate end-capped) was dissolved.
- the primer was applied to the tissue surface with a brush.
- Priming technology is described in more detail in U.S. Pat. Nos. 5,800,373 and 5,844,016 to Hubbell, et al.; synthesis of the 35KTA2 macromers is described in WO 98/12243 by Focal; and synthesis of the 3.3KLA2 macromer is described in U.S. Pat. No. 5,410,016 to Hubbell et al., along with techniques for photopolymerization.
- Irgacure ® 651 Photoinitiator sometimes added as solution in where the weight of. VC is twice the weight of Irgacure ®.
- Adherence test involves inserting 20 gauge needle at base of gel and pulling up parallel to base.
- Examples 2-27 demonstrate certain formulations that polymerize to produce hydrogels acceptable for orthopedic applications, as well as selected control materials.
- Example 2 shows a “classic” hydrogel which, although it contains some (4.4%) DAA, and although it adheres well to tissue, has a high swelling and low final solids concentration. It is too soft for use in a load-bearing application, because its final polymer concentration (6.36% solids) is too low.
- Example 3 shows that DAA without a crosslinker forms a plastic with a yield point, rather than a highly resilient material.
- Examples 4, 5, 7, and 9 show variations of the preferred formula, which is depicted in example 8. Like example 8, these examples also yield hydrogel materials useful for orthopedic applications.
- Example 6 shows partial substitution of DAA with a charged monomer.
- Examples 10 and 11 show the use of a polyether urethane backbone, the synthesis of which is described below in Example 28.
- Example 12 shows use of a surfactant, polyoxyethylene sorbitan monolaurate (Tween® 20), which has been derivatized to contain about three acrylic groups per molecule, as a hydrophilic crosslinking macromer.
- a surfactant polyoxyethylene sorbitan monolaurate (Tween® 20)
- Tween® 20 polyoxyethylene sorbitan monolaurate
- Examples 13 and 14 show adherence of the preferred formula of Examples 1 or 8 to various tissues.
- Example 13 also compares the preferred formulation as a solution (after heating) versus as a paste, as obtained without heating, or on thawing from the frozen state without heating. The paste is less adherent, giving “Moderate” rather than “Excellent” adhesion.
- Example 15 summarizes a subcutaneous implantation experiment (in rats) with the preferred formulation. Good biocompatibility (minimal tissue response) was found.
- Examples 16 and 17 show that complete substitution of N-isopropyl acrylamide (NIPAM) and vinylcaprolactam (VC) for DAA gives gels that swell extensively and thereby lose toughness.
- Example 18 shows that VC can partially substitute for DAA with retention of desirable properties. Since DAA is more hydrophobic than VC, this effect may demonstrate desirability for hydrophobicity in the material.
- Examples 19-21 show non-water-containing formulations, made by co-dissolving the macromers and the monomers with heating.
- Example 19 is unsuitable;
- Example 20 is marginal but acceptable; and
- Example 21 is essentially the same as Example 18, which contained water during
- Examples 4, 5, 7, and 9 show variations of the preferred formula, which is depicted in example 8. Like example 8, these examples also yield hydrogel materials useful for orthopedic applications.
- Example 6 shows partial substitution of DAA with a charged monomer.
- Examples 10 and 11 show the use of a polyether urethane backbone, the synthesis of which is described below in Example 28.
- Example 12 shows use of a surfactant, polyoxyethylene sorbitan monolaurate (Tween® 20), which has been derivatized to contain about three acrylic groups per molecule, as a hydrophilic crosslinking macromer.
- a surfactant polyoxyethylene sorbitan monolaurate (Tween® 20)
- Tween® 20 polyoxyethylene sorbitan monolaurate
- Examples 13 and 14 show adherence of the preferred formula of Examples 1 or 8 to various tissues.
- Example 13 also compares the preferred formulation as a solution (after heating) versus as a paste, as obtained without heating, or on thawing from the frozen state without heating. The paste is less adherent, giving “Moderate” rather than “Excellent” adhesion.
- Example 15 summarizes a subcutaneous implantation experiment (in rats) with the preferred formulation. Good biocompatibility (minimal tissue response) was found.
- Examples 16 and 17 show that complete substitution of N-isopropyl acrylamide (NIPAM) and vinylcaprolactam (VC) for DAA gives gels that swell extensively and thereby lose toughness.
- Example 18 shows that VC can partially substitute for DAA with retention of desirable properties. Since DAA is more hydrophobic than VC, this effect may demonstrate desirability for hydrophobicity in the material.
- Examples 19-21 show non-water-containing formulations, made by co-dissolving the macromers and the monomers with heating.
- Example 19 is unsuitable;
- Example 20 is marginal but acceptable; and
- Example 21 is essentially the same as Example 18, which contained water during polymerization.
- Example 20 uses methyl vinylacrylamide (MVA) as monomer, and does not contain DAA.
- MVA methyl vinylacrylamide
- Examples 22-26 show various formulations in which the macromer is an acrylated poloxamer (i.e., PEG-PPO block copolymer), made by simple acrylation of commercial materials, such as the Pluronic® surfactants by BASF. These macromers, which have hydrophobic segments, can also form hydrogel materials for orthopedic use. However, the formulation with VC is relatively brittle, while the DAA-containing formulae are acceptable.
- PEG-PPO block copolymer acrylated poloxamer
- Pluronic® surfactants by BASF.
- Example 27 shows that VC alone is not satisfactory, as expected from the absence of crosslinking.
- a macromer with a polyurethane backbone was prepared by reacting 1,4-butanediol (1.27 g, 0.0147 m), PET, MW 3,400 (50.00 g, 0.0147 m) and 1,6-diisocyanatohexane (4.66 g, 0.0277 m) in toluene with dibutyltin dilaurate catalyst (80° C., 4 hr.).
- the resulting macrodiol was acrylated with acryloyl chloride and isolated by precipitation with hexane.
- This material was used in an adhesive/sealant fonnulation, shown in Example 10, by mixing it (3.0 g) into a solution of DAA (3.0 g) in water (4.0 g). This solution was warmed and 6% aqueous t-butyl hydroperoxide (42 mL) along with molten Irgacure® 651 (15 ⁇ L) were mixed in. The resulting formulation was treated to remove bubbles by centrifugation or allowing it to stand at ambient and stored at ⁇ 40° or used to prepare hydrogel.
- Example 11 A similar preparation was used in Example 11 by mixing 2 g of the acrylated polyurethane with a solution containing 6 g of DAA and 2 g of water; the other ingredients were the same.
- a 10 day study showed that the hydrogel remained in place with no apparent damage. Surrounding tissue was found to be comparable to untreated, injured controls, demonstrating short-term biocompatibility. In particular, histological sections showed no apparent damage or injury to adjacent cartilage, either in the chondrocytes or in the matrix. The materials used in this study had previously passed cytocompatibility tests and were sterile and non-pyrogenic. The results indicated that the hydrogel replaced cartilage tissue, caused no damage, and allowed function of the joint for the duration of the study.
- Acryloyllactic acid-methyl ester was designed for the formation of orthopedic materials.
- Acryloyllactic acid-methyl ester (ALM; methyl acryloyl lactate; the acrylic ester of lactic acid methyl ester; CH 2 ⁇ CH—C( ⁇ O)OCH(CH 3 )C( ⁇ O)OCH 3 ) was prepared as follows.
- a 15.61 g amount of methyl lactate (isomer S( ⁇ )) in 81 mL toluene was reacted with 13.79 g acryloyl chloride in the presence of 15.79 g triethylamine at less than 20° C.
- the acryloyl chloride was added drop-wise with cooling to the reaction mixture containing the TEA, to control the exotherm.
- the resultant TEA.HCl salt was filtered off; and the ALM/toluene solution was purified by passing it through a column containing 15 g alumina, and stabilized with 6.5 mg hydroquinone.
- the ALM product was isolated by removal of toluene under vacuum using a rotary evaporator.
- the ALM yield ranged from 72% to 75%. Based on analysis by Proton-Nuclear Magnetic Resonance Spectroscopy (H-NMR), the amber product typically contains: 94.4% ALM, 1.0% acryloyllactic acid ethyl ester (ALE), 0.0% TEA.HCl, 1.43% methyl lactate, 0.72% acrylic acid, and 1.45% toluene.
- H-NMR Proton-Nuclear Magnetic Resonance Spectroscopy
- the ALM was distilled under vacuum at 60-62 C and 0.8-0.95 mTorr, yielding a clear, colorless fluid. Based on analysis by H-NMR, the ALM typically contains: 98.01% ALM, 0.74% ALE, 0.0% TEA.HCl, 1.43% methyl lactate, 0.22% acrylic acid, and 0.02% toluene.
- Polymer A A neat solution of 150 g ALM was auto-polymerized under vacuum at 60-70° C. for about 20 minutes (exotherm to 120° C.).
- the very elastic, ultra high molecular weight (MW) polymer required breaking of the reaction vessel for removal.
- the polymer swelled and or showed partial solubility in most organic solvents, including chloroform, methylene chloride, dimethyl sulfoxide, tetrahydrofuran, hexafluorisopropanol, but was not soluble in water. This material hydrated 2.7% over a period of 3 days at 37° C. and had a modulus of 338.64 kPa after vacuum drying.
- Polymer B A neat solution of 1.95 g ALM was polymerized under N 2 with 10.0 mg benzoyl peroxide as initiator by heating at 60-70° C. for about 5 minutes.
- the elastic, high MW polymer required breaking of the reaction vessel for removal. This polymer had a modulus of 29.55 kPa.
- Polymer C A low MW equivalent was prepared by polymerization of 2.45 g ALM with 30.2 mg benzoyl peroxide as initiator by heating at 60-70° C. for about 5 minutes. This polymer had a modulus of 16.2 kPa. Both Polymers B and C were very flexible and soluble in most organic solvents, including chloroform, methylene chloride, dimethyl sulfoxide, tetrahydrofuran, but were not soluble in water.
- a 0.2261 g piece of the high MW polyALM (Polymer B) was incubated with about 30 mL of phosphate buffer pH 7.4 at 37° C.
- the sample weight was 0.2272 g after 3 days.
- the material was dried for 24 hrs under vacuum at room temperature. The weight decreased to 0.2212 g, indicating an equilibrium hydration of about 2.2%.
- the hydrated polyALM was lubricious rather than tacky.
- the modulus of this incubated polymer was 44.18 kPa.
- Polymers A, B, and C were incubated at 85° C. in water at pH 11.8-12.5. After 8 days, Polymer A had substantially dissolved. The aqueous solution was viscous. Polymers B and C substantially dissolved over 6 days at 85° C. The aqueous solutions were somewhat viscous.
- polymers of ALM can be prepared to have moduli, toughness and hydration appropriate for application to orthopedic tissues, and further are degradable in an accelerated test.
- ALM was copolymerized with other materials. Combinations tested included:
- Examples 30 and 31 demonstrate that a material useful as an orthopedic repair material, as defined herein, can be made from a degradable material. Based on these examples, one of skill in the art can make a new material, which has the desired properties of low swelling at high proportions of solids, high tensile modulus, significant elongation to failure, biocompatibility, and adherence.
- Step 1 Synthesis of ALA (Acryloyl lactic acid).
- the ALM material described above is a convenient starting material for this synthesis, because methyl lactate is commercially available.
- Acryloyl chloride can be substituted with other active ethylenically unsaturated compounds, for example acryl imidazole or methacryl bromide or cinnamoyl succinimide, depending on the active group desired in the AHK material.
- ALM is hydrolyzed to ALA by selective de-esterification in basic aqueous solution.
- the reaction takes advantage of the more rapid hydrolysis of the methyl lactate ester (the H to K bond) compared to the acryloyl-lactyl ester (the A to H bond).
- 10.03 g of ALM (92.92% pure) is dispersed in 90 mL of water and hydrolyzed with 5.45 mL of 10 N sodium hydroxide to the Na-acryloyllactic acid salt.
- the base is added dropwise at 20-25° C.
- the Na-acryloyllactic acid salt is converted to acryloyllactic acid (ALA) with 6N HCl at pH 1.0.
- the ALA is extracted from the aqueous phase with 112 mL toluene overnight using a liquid-liquid extractor. Residual moisture is removed with 6 g of magnesium sulfate. After filtration of the magnesium sulfate, the toluene is removed under vacuum using a rotary evaporator. The concentrated ALA is a yellow colored oil.
- Typical analysis of ALA by 1 H-NMR % ALA % Toluene % Lactic Acid % Acrylic Acid 95.78 2.53 0.16 1.53 It was determined experimentally that the above conditions optimized the yield of acryloyllactic acid (ALA), in that most of the ALM had hydrolyzed but significant hydrolysis of the acryloyl-lactyl ester bond had not begun.
- ALA acryloyllactic acid
- Step 2 Synthesis of ALC (acryloyl lactoyl chloride, CH 2 ⁇ CH—CO—OCH—O—CH(CH 3 )—CO—Cl). This step is a straightforward activation reaction for a carboxylic acid, and many procedures are known for such activation.
- Step 3 Synthesis of AHK esters. This is simply a reaction of an active carboxyl, such as an acyl chloride, with an alcohol. Many such procedures are known in the literature. The following hypothetical experiment illustrates the general method.
- this ALC containing solution directly to a desired alcohol in a suitable solvent along with a suitable amine (e.g. pyridine or triethylamine) to scavenge generated acid.
- a suitable amine e.g. pyridine or triethylamine
- the above THF solution containing ALC can be added to a solution of 0.9% equivalent of cholesterol in toluene, based on the calculated ALA content and triethylamine.
- the cholesterol ester of ALA is obtained after removal of the amine salt and concentration on a rotary evaporator under reduced pressure.
- the activation of the free acid (e.g. ALA) to the activated ester (e.g., ALC) and subsequent synthesis of an AHK ester can also be accomplished as a single or stepwise “one-pot” activation, using suitable acylating agents—for example, dicyclohexylcarbodiimide (DCC) with a catalytic amount of dimethylaninopyridine.
- suitable acylating agents for example, dicyclohexylcarbodiimide (DCC) with a catalytic amount of dimethylaninopyridine.
- DCC dicyclohexylcarbodiimide
- a variety of groups can be used as leaving groups C. These include a halogen, a residue of a succinimidyl group, a residue of imidazole, a residue of a thioester, nitrophenols, pyridines, and o-acyl ureas.
- the key requirement is that the leaving group be readily displacable
- Polyvinyl alcohol (PVA) was reacted with ALC to form the monomer acryloyl-lactyl-PVA.
- ALC was prepared essentially as described above.
- PVA from Aldrich had a stated molecular weight of 10 kDa (however the actual weight was from 9 kDa to 10 kDa) and was stated to be about 80% hydrolyzed.
- Ten grams of PVA were placed in a 3-neck 250 mL flask and pyridine was added to about 200 mL final volume. The mixture was stirred under nitrogen to dissolve the PVA. The flask was heated to about 95° C. and distillation of pyridine began.
- the PVA began to precipitate at about 120° C.; addition of about 200 mL of dimethylacetamide (DMAC) produced a homogenous solution and reduced the temperature to about 70° C. After reduction in volume by distillation to about 200 mL, the mixture was allowed to cool to 60° C. and ALC (450 ⁇ L; approximately 97% purity and activity) was added.
- DMAC dimethylacetamide
- the mixture was maintained at 60° C. under stirring and nitrogen for 20 minutes. Then it was precipitated by pouring it into 1800 mL of toluene with vigorous stirring. The gelatinous precipitate was vacuum filtered. The precipitate was mixed with 200 mL hexanes, and filtered; this was repeated twice. A fine damp powder was obtained and was vacuum dried at 40° C. overnight.
- the monomer can include a polymer as the “K” group, and its properties can be tailored by variable degrees of derivatization.
Abstract
Hydrogels intended for orthopedic applications, including repair and regeneration of cartilage, bone, joint surfaces and related tissues, must possess greater strength and toughness than hydrogels used in soft tissue repair. A hydrogel formulation is provided which has high strength, toughness, a suitable mechanical modulus and low equilibrium hydration. It may also have controlled porosity or degradation time. It can be made to polymerize in situ with high (“good” to “excellent”) adherence to target tissue or surfaces. A preferred formulation for forming such gels comprises 40 to 80% by weight of a low-molecular weight polar monomer and 30 to 10% of a hydrophilic macromeric crosslinker.
Description
- This application claims priority to U.S. Ser. No. 60/153,190, filed Sep. 10, 1999.
- This invention is generally in the field of treatments of disease, particularly disease of skeletal or orthopedic tissues such as cartilage and bone, using polymeric materials having high adherence to tissue, low degree of swelling, toughness and biocompatibility.
- Hydrogel materials are useful in coating, sealing and adhesion of soft tissues, for example as described in U.S. Pat. No. 5,410,016 to Hubbell et al., U.S. Pat. No. 5,800,373 to Melanson et al., and U.S. Pat. Nos. 5,844,016, and 5,900,245 to Sawhney et al. Important properties of these hydrogels are their biocompatibility, their ability to adhere strongly to tissue, and good mechanical compliance, which is appropriately matched to that of the tissue. Biocompatibility is achieved by the use of materials that are especially compatible with tissue, such as polyalkylene oxides, and by a high water content, similar to that of the tissue being coated.
- However, these gels are less useful in situations in which the gels are subject to high mechanical stress. An example of such a situation is in the repair of bone and other skeletally related tissues, such as cartilage, the tibial meniscus, tendons and ligaments, spinal disks, and muscle (collectively, “orthopedic tissues”), or in composite implants intended for such uses. Repair of injuries, disease or defects of orthopedic tissues can be difficult because the gel needs to offer protection to the structures under mechanical stress. Tight adherence to the substrate is often beneficial in achieving this purpose. Repair of articular cartilage is especially difficult. A surface must be provided which is resistant to abrasion and provides cushioning during regeneration and maturation of the cartilage, for example, following implants of tissues, cells or aggregates. On the other hand, appropriate stress transmitted to the cells facilitates appropriate alignment and generation of a normal intercellular matrix. Similar considerations apply to bone regeneration, especially at joints.
- Traditional hydrogels are not strong enough to withstand the applied stresses, particularly over the length of time required, especially for long periods of time such as those required for regeneration of bone or connective tissue. Such gels also tend to swell extensively in aqueous environments, which can interfere with mechanical properties of the injured joint or other site. Moreover, hydrogels do not tend to adhere strongly to tissue, especially to moist tissue, or when pre-formed before application to tissue. On the other hand, traditional solid implants (which typically are formed of hydrophobic materials) can be too rigid and brittle, thereby impeding or preventing tissue repair or regeneration. They may also lack lubricity, which can compromise performance in joints as well as pose a risk of abrasion of the opposing surface.
- A material that has the appropriate balance of strength and compliance as well as the biocompatibility of a hydrogel, and that has strong adherence to orthopedic tissues, is needed.
- It is an object of the present invention to provide biocompatible hydrogels which strongly adhere to orthopedic tissues.
- It is another object of the present invention to provide hydrogels with strong mechanical properties.
- It is another object of the present invention to provide monomers from which hydrogels with strong mechanical properties can be formed, and methods of use thereof.
- Polymeric materials have been developed which can be effective in treatment of orthopedic tissues, such as cartilage, bone and accessory structures, and implants. In one embodiment, the material includes a mixture of two components which copolymerize to form a hydrogel that contains hydrophilic and hydrophobic regions. The first component is covalently-crosslinkable, hydrophilic, polymeric, of high biocompatibility, and optionally spontaneously hydrolyzing (“biodegradable”). It is preferably sufficiently hydrophilic to be water-soluble at a temperature between about 0 and 70° C. The second component is more hydrophobic (although it is preferably water-soluble under the same conditions), is covalently polymerizable, provides structural strength and limits the water absorption capacity of the formed gel. Upon reaction in situ in the presence of polymerization initiators bound to or adhered to the tissue (“priming systems”), the resulting polymerized hydrogel adheres tightly to the tissues, and has suitable mechanical properties, including toughness, strength and resiliency to facilitate repair or regeneration of the tissue. It also remains as a hydrogel, retaining the advantages of biocompatibility and lubricity. The hydrogel is optionally biodegradable.
- In a second embodiment, the material is predominantly a high-molecular weight, covalently-polymerizable macromer, which is soluble or paste-like at high concentration (e.g., 40% or more by weight) in the formulation, and which can be polymerized to form a tough, adherent, biocompatible coating on tissue.
- In a third embodiment, monomers of molecular weight less than about 1 kDa, or mixtures of monomers, are the sole or principal precursors of the material. A significant fraction of the weight of the solution, for example 40% or more, is amphiphilic monomers; functionally hydrophobic monomers form less than about 50% of the mixture; macromers comprise from zero to less than about 30% of the weight, and water is from zero to less than about 40% of the weight.
- The polymerized materials have a controlled, low degree of swelling on continued exposure to water, combined with a tensile modulus which may be in excess of 1 MPa and also having a significant elongation to break (e.g., 10% or more). This combination of properties makes the materials tough, resilient, and able to withstand cyclic mechanical stress for extended periods. The material can also be made porous, and thereby permissive of cell or tissue ingrowth in the process of tissue repair. Porosity formation may be intrinsic to the materials or may be provided by pore-forming excipients or processes.
- Methods of use of such materials in the treatment, repair or regeneration of tissues are described.
-
FIG. 1 is a graph of the mechanical properties, tensile strength and modulus, psi, and percent elongation. These are shown for the material as initially formed, for the material after hydration (swelling) for 1 day at 37° C., and for the material after accelerated incubation for 13 days at 57° C. - A. Required Hydrogel Properties
- A range of materials can be used to obtain the desired hydrogel. The key attributes of the formed hydrogel are low swelling at high proportions of solids, high tensile modulus, significant elongation to failure, biocompatibility, and adherence, as defined below.
- SWELLING and HYDRATION: Swelling results from the absorption of water by a formed polymeric material, which can be initially dry or already contain water. It is expressed herein as the percent increase in weight of a material from its initial state to a state in equilibrium with an aqueous solution, such as water or a bodily fluid. For example, if a piece of material had a weight of 1 g when formed, and 2 g after equilibration with water, it would exhibit a swelling of 100%. Direct measurement of volume could also be used to determine the degree of swelling. An appropriate time and temperature for obtaining near-equilibrium hydration of a material, in configurement relevant to implant application, is incubation for about 24 hrs in water, ideally at 37° C. to simulate body temperature. However, a simple overnight incubation at room temperature normally gives a hydration, or degree of swelling, that is adequately close to true equilibrium. (It should be noted that this may not be true for other materials—for example, conventional hydrophobic thermoplastics, such as polyethylene).
- Prior art gels containing similar materials, such as those described in U.S. Pat. No. 5,410,016 to Hubbell, et al., composed largely or entirely of crosslinked hydrophilic macromers, tend to swell several hundred percent. These gels are highly “elastic” (compliant) and correspondingly do not resist stress well. Hydrogels with relatively little swelling can be made, for example, from dilute crosslinked polyacrylamide, such as gels used for electrophoresis. However, these gels are very brittle and weak and are not suited for the purposes described herein. In these cases, the lack of swelling is achieved in part by having a low percentage of gel-forming solids in the composition. Prior art non-gel materials, such as polylactide, do not swell significantly, but have such a high modulus and hardness that they have a low elastic limit and tend to deform irreversibly or fracture under stress.
- Gels with a low degree of swelling are preferred. The most preferred gels have an equilibrium swelling of about 150% or less. Preferred gels have a swelling of about 200% or less. Gels with swelling below about 300% are potentially of use. Low degrees of swelling are achieved at high concentrations of gel-forming solids. Suitable ranges of gel-forming solids at the time of gel formation are at least about 30% by weight, preferably over 40%, more preferably over 50%, and yet more preferably over 60%. The preferred embodiments have over 70% solids at the time of formation. Correspondingly, the concentration of solids after equilibrium swelling is also high. The gel-forming materials should comprise at least 20% by weight of the gel after swelling to equilibrium in bodily fluids. Higher values are preferable, such as 30% or more. The preferred embodiments have 40% or higher solids after equilibration with water.
- MODULUS: A material's modulus is the ratio of stress (applied force per unit area) over strain (ratio of compressed or stretched length to original length). It is expressed in units of force per unit area, such as Pascals or PSI, and is typically measured quantitatively on a device such as an Instron® mechanical tester. The gels described herein have a modulus that is quite high for a hydrogel. The most preferred values of the tensile or compressive modulus, at small strains and after swelling, are over 1 megaPascal (MPa). Gels with a post-swelling modulus of 500 kiloPascals (kPa) or greater are preferred. Gels with a modulus of 100 kPa, preferably 200 kPa or more, are of use in the invention. Gels with a modulus above about 50 kPa can be used in low-stress situations.
- ELONGATION TO FAILURE: For the purposes described herein, elongation to failure is the strain (degree of deformation) at which the material fails (breaks), expressed as a percent of the material's original length. It is also measured on an Instron® tester or similar device. A material with a 100% elongation (strain) at failure is double its original length. Materials with a significant elongation to failure are preferred. Preferred materials have values above about 300%, and suitable materials can have values in the range of about 25% to over 800% if other properties are appropriate. In addition to the elongation to failure value, having a measurable range in which the material is elastic, i.e., returns to its original shape, is important for its durability, particularly under the conditions found in joints and other orthopedic tissues. As used herein the term “elastic” includes “substantially elastic” and “predominantly elastic” and is used to describe materials that have low modulus in tension or compression and high elongation to break. Substantially elastic materials include materials in which up to 25% of the deformation can be irreversible (plastic) deformation. The deformation of preferred materials is substantially elastic.
- TOUGHNESS: The values of elongation and modulus can be combined to give a quantitative measurement of toughness, which is the area under the stress-strain curve to the failure point. However, there are several potential complicating factors, such as rate of elongation and shape of the test piece. For the purposes described herein, the area under the curve should only be used as a means of comparison of related samples. “Toughness” is used herein only in a comparative sense unless otherwise specified. A qualitative measure of toughness, for gels of a particular thickness, is obtained by compressing a piece of gel between the jaws of a locking surgical hemostat. A standard compressive load can be achieved by specifying how many “clicks”—detents giving progressively higher compressive force—on the locking mechanism are used. Gels that do not fracture in this test are tougher than those that do fracture.
- BIOCOMPATIBILITY: A material is biocompatible if its implantation does not provoke a severe local or systemic inflammatory reaction. This is in distinction to the transient mild inflammatory response that accompanies essentially all implants. Biocompatibility may be determined by histological examination of the implant site at various times after implantation. One sign of poor biocompatibility can be a severe, chronic, unresolved phagocytic response at the site. Another sign of poor biocompatibility can be necrosis or regression of tissue at the site.
- ADHERENCE: Adherence of gels to tissue can be optimized by techniques that employ functional primers, as described in U.S. Pat. No. 5,800,373 to Melanson et al., U.S. Pat. Nos. 5,844,016, or 5,900,245 to Sawhney et al. for gels formed by polymerization of ethylenically unsaturated precursors. Suitable gel compositions form strong bonds to tissue. These techniques are also applicable to creating strong adherence of the materials to tissue, including tissue to which it is difficult to obtain adherence by conventional methods, for example, cartilage.
- A general procedure for applying materials to orthopedic tissue involves brushing or dabbing primer over a larger area than that over which the material is applied. Thereafter, material is brushed or dabbed over the deposited primer. Then bulk material is applied by dripping (if liquid) or spreading (if paste) over yet a smaller area of the treated zone. Then light (at appropriate wavelength, intensity, distance and for an appropriate time) is applied at each zone, or other means of polymerizing the material are used.
- Adherence of the hydrogel to tissue may be determined by passing a 20 gauge needle through the base of the hydrogel near the tissue interface, then grasping the needle at both ends, and finally lifting the needle parallel to the tissue while holding down the test object. The needle eventually releases either via adhesive failure of the hydrogel to the tissue, or by cohesive failure of the hydrogel or tissue. The examples below show many primed hydrogels that provided bonds strong enough to cause cohesive failure.
- Adherence may be qualitatively rated as follows. “Excellent adherence” means that upon application of force to the needle, cohesive failure of tissue or gel was observed. “Moderate adherence” means that upon application of force to the needle failure was partially cohesive and partially adhesive. “Fair adherence” means that the mode of failure was adhesive failure. “Poor adherence” means that a light force, as compared with the force needed to cause cohesive failure, was needed to cause adhesive failure. Preferred gels have moderate to excellent adherence on this scale.
- LUBRICITY is the quality of a surface that confers relatively low frictional forces between that surface and an opposing surface, often via a thin film of liquid material on the surface that wets both surfaces. The fluid can be adsorbed to the surface, or exuded by the surface, or both. Hydrogels tend to be naturally lubricious. In addition, hydrogel surfaces have an innate affinity for water. Natural cartilage has a similar property.
- Gel or hydrogel, as used herein, includes the traditional hydrogel, in which polymer and water each form continuous phases. As used herein, these terms may also include materials absorbing at least 5% of an aqueous phase, which is not necessarily continuous. As used herein “functionally hydrophobic monomers” means monomers including reactive groups and hydrophobic groups and having up to one group that is no more hydrophilic than an alkyl ester or a dialkyl amide. Examples of functionally hydrophobic monomers include vinyl caprolactam (VC), methyl acrylate, methyl methacrylate, styrene, N-vinyl pyrrolidone (VP), and N-vinyl imidazole (VI). In contrast, examples of amphiphilic monomers include diacetone acrylamide (DAA), vinyloxyethanol (VOE), 2-acrylamido-2-methylpropane (AMPS), and methyl acryloyl lactate (ALM) and its relatives.
- B. Gel-Forming Precursors
- The gel-forming materials comprise reactive polymers (macromers), with molecular weights ranging from about 500 Daltons (Da) to about 200,000 Da, measured by any conventional technique. These macromers contain hydrophobic and hydrophilic regions and are combined, in most embodiments, with reactive low molecular weight monomers, having molecular weights below about 1000 Da. The combination is preferably characterized by being sufficiently hydrophobic after polymerization to provide hydrogels with low swelling and relatively high solids content after equilibration with water. For example, the preferred polymeric solids concentration after equilibration of the formed gel with water or bodily fluids will be in the range of from about 15% wt/wt to above 70% wt/wt. This characteristic may involve phase separation or coacervate formation during polymerization, leading to a heterogeneous hydrogel. Some products may be porous.
- A variety of macromers that can be used to form the hydrogel are described in the literature. A preferred family based on a PEG (polyethylene glycol; poly(ethylene oxide)) backbone and acrylate termination is described in U.S. Pat. No. 5,410,016 to Hubbell et al., U.S. Pat. No. 5,573,934 to Hubbell et al., U.S. Pat. No. 5,800,373 to Melanson et al., U.S. Pat. No. 5,844,016 and U.S. Pat. No. 5,900,245 to Swahney et al. and in International Patent Publication No. WO 96/29370 by Board of Regents, University of Texas, and WO 98/2243 and WO 99/07417 by Focal. Design, synthesis and use of such molecules are described. These molecules can readily be adapted for use in the system described herein with little experimentation. Other suitable materials, or materials readily modified to be suitable, are described in U.S. Pat. No. 4,938,763 to Dunn, et al., U.S. Pat. Nos. 5,100,992 and 4,826,945 to Cohn et al, U.S. Pat. Nos. 4,741,872 and 5,160,745 to De Luca et al, U.S. Pat. No. 4,511,478 to Nowinski et al., U.S. Pat. No. 5,198,507 to Kohn et al., U.S. Pat. No. 5,219,564 to Zalipsky et al.; WO 98/00170 by Hennink et al; WO 99/03454 by Hubbell et al.; and U.S. Pat. No. 5,854,382 to Loomis et al.
- Macromers which polymerize to form hydrogels via condensation or electrophile/nucleophile chemistry are described in numerous publications, including U.S. Pat. Nos. 5,744,545, 5,614,587, and 5,874,500 to Rhee et al; U.S. Pat. No. 5,514,379 to Weissleder and Bogdanov; U.S. Pat. No. 5,173,301 to Itoh and Matsuda; U.S. Pat. No. 5,583,114 to Barrows et al, and U.S. Pat. No. 4,057,535 to Lipatova et al. Other examples include U.S. Pat. No. 4,839,345 to Doi, et al.; U.S. Pat. Nos. 5,252,714, 5,739,208 and 5,672,662 to Harris, et al.; U.S. Pat. Nos. 4,740,534, 4,994.542, and 4,806,614 to Matsuda, et al.; U.S. Pat. No. 4,804,691 to English et al.; and WO 99/14259 by Harris.
- Although poly(ethylene glycol) (PEG) is preferred for forming the macromeric backbone because of its biocompatibility and stability, other macromolecules are also useful. These include, as illustrated below, PEG-PPO (copolymers of polyethylene glycol and polypropylene oxide), hydrophilic segmented urethanes, and multivalently-derivatizable surfactants, in each case derivatized to carry reactive groups. A wide variety of other hydrophilic natural and synthetic polymers are suitable for use in backbones for forming macromers to make the bydrogels. These include hydrophilic synthetic polymers, such as polyvinylpyrrolidone, polyvinyl alcohol (including partially deacetylated polyvinylacetate), poly[meth]acrylic acid and poly[meth]acrylamides (where “[meth]” indicates optional methyl substitution of the acrylate group), and mixed water-soluble copolymers such as copolymers of maleic acid and ethylene. Natural, synthetic and semi-synthetic saccharides and polysaccharides include hydroxyalkyl celluloses, dextran, Ficoll™, bacterial fermentation products such as xanthan or gellan, and food-grade materials such as alginates, carrageenans, pectins, agars, glucomannans, galactomannans, hyaluronic acid, heparin, chondroitin sulfate, and other glycosaminoglycans, and starch. Proteins and nucleic acids can be used. Multivalently-substitutable lipids, such as “dimer fatty acid”, monoacylglycerol, phosphatidyl inositol, cardiolipin, and derivatives thereof, can also be used as components of a backbone for forming a macromer.
- In some cases, systems containing only macromeric components can be used. It is important in this case that at least some of the macromeric components have significant hydrophobic character, to form hydrophobic domains on polymerization. Suitable backbones for such a macromer, to which polymerizable groups can be grafted, include water-soluble or water-dispersible copolymers of ethylene oxide with propylene oxide and/or butylene oxide, and polyurethanes, polyesters and polyamides containing hydrophilic segments.
- Low molecular weight monomers that are useful in the hydrogel materials share several key properties. The first property is that the monomers should react appropriately in the presence of the other components of the system, in particular a macromeric component or water, when either or both are present. To obtain this property, it is preferable, but not required, that the monomers be miscible with other components of the material. One key material is water at room or elevated temperature, up to about 100° C., with which the monomer is preferably soluble or miscible to a significant extent, such as 30% wt/vol., preferably 40% wt/vol., and most preferably 50% wt/vol. or higher. Alternatively, the monomer can dissolve in or be a solvent for a macromer under similar conditions, in the presence or the absence of water. However, compositions formed of partially immiscible macromers and monomers can be suitable if the polymerization reaction gives the required properties for the final polymerized materials.
- The second property is that the monomer should impart the characteristic of low swelling in aqueous solution to the hydrogel upon polymerization. One mechanism for providing decreased swelling is a significant decrease in water absorption of a polymer formed predominantly from the monomer by polymerization. At the high concentration of solids in the hydrogels, a distinctly heterogeneous hydrogel may form upon polymerization, or during subsequent swelling in aqueous solutions.
- Thirdly, the product formed from the polymerization of the monomer and the macromer must contain water, or must be capable of absorbing water. This can be as little as 2% to 5% by weight at equilibrium, but preferably is at least 10% and more preferably is 20% or more. This water is important for providing lubricity to the polymerized composition. The material does not need to be a hydrogel at the conclusion of polymerization, if it can absorb or adsorb sufficient water to become lubricious when in contact with bodily fluids.
- Unsaturated monomers which have been found experimentally to be preferable for this function include diacetone acrylamide (“DAA”; CAS 2873-97-4). The minimum effective concentration for DAA is about 30% as sole monomer, but may be less in blends with other monomers. These include vinylcaprolactan (VC), vinyloxyethanol (VOE), or up to about 10% of 2-acrylamido 2-methyl propanesulfonic acid (AMPS). It is believed that other low molecular weight monomers are suitable when blended with DAA; suitability and limiting concentrations are readily determined by experimentation. The useful range of monomers increases substantially when the macromer has significant hydrophobic segments or domains.
- It is believed that the effectiveness of the preferred low molecular weight monomers is due to a balance of hydrophobic and hydrophilic domains or segments, in the composition after polymerization. The hydrophobic domains serve to control and limit water uptake, and reinforce the polymerized composition which functions as a water-swollen matrix. This is why it is important that at least some of the macromer, or a segment of the macromer, is hydrophilic, and remains hydrophilic after the polymerization; and that a segment of the macromer, or of the monomer after polymerization, be hydrophobic.
- A representative class of preferred monomers are acryloyllactic acid-methyl esters (ALM). Methyl acryloyl lactate; the acrylic ester of lactic acid methyl ester; CH2═CH—C(═O)OCH(CH3)C(═O)OCH3) is prepared as described in Example 30. The ALM monomer can be viewed as being composed of three parts, generally designated “AHK”. “A” designates a reactive group, which in ALM is the residue of acrylic acid after esterification to the hydroxy group of lactic acid. “H” designates a hydroxy carboxylic acid, which is lactic acid in ALM. Finally, “K” designates an alkyl group, or another relatively inert group, containing an alcohol group before esterification to the H carboxyl group. In ALM, the K group is the residue of methanol.
- It will be appreciated by those of skill in the art that variants of the ALM structure can readily be manufactured, and will allow the tailoring of the properties of the monomer to a particular tissue situation. For example, each of these groups can be replaced with analogous groups of the same class, resulting in variations in the hydrophobicity, crystallinity, and hydrolysis stability of the materials resulting from the polymerization of these monomers. Thus, A can be selected from acrylic acid and methacrylic acid, or from other acids carrying unsaturation. These include crotonic, isocrotonic, tiglic, angelic, and cinnamic acids, and unsaturated diacids including maleic, fumaric, citraconic, mesaconic, itaconic, citric and isocitric acids, as well as monoesters or monoamides of the dicarboxylic acids.
- H can be any of a large number of hydroxy carboxylic acids. These are the residues widely used to create degradability in polymers, so that they will degrade to small, metabolizable or excretable units, in a reasonably predictable way in the body. The most commonly used of these are the lower alkyl hydroxy acids, including glycolic acid, lactic acid, 3-hydroxy-propanoic acid, 2-, 3-, or 4-hydroxybutyric acid, the various isomers of hydroxypentanoic acid (including valeric acid), and the hydroxyhexanoic acid isomers, including 2-caproic acid and 6-caproic acid (epsilon-caproic acid). Many of these hydroxy acids are available in “lactide” or lactone forms, which can simplify synthesis. Other commonly used hydroxy acids include the lactone and hydrolyzed forms of dioxanone (1,4-dioxan-2-one) and other cyclic dioxanones, and of similar 1-oxan-2-one ethers with 5 and 7 membered rings.
- In general, when H is formed from the 2-hydroxy acids, the monomers and the corresponding polymers and copolymers tend to degrade by hydrolysis most rapidly, followed by the 3-, 4-, 5-, and 6-hydroxyacids. This is due mainly to the hydrophobicity of the higher hydroxy acids. Hydrophobicity tends to exclude water from the labile ester bond between the H and the K group, which slows degradation. Hydrophobicity can also be affected by increasing the hydrocarbon content of the hydroxy acid by incorporation of side chains, such as the methyl group in lactic acid. Likewise, increased hydrophobicity of the K group also slows hydrolysis. Steric protection of the ester linkage from water would also slow hydrolysis. Degradation time is also affected by the crystallinity of the polymer or copolymer. Increases in crystallinity tend to exclude water from the labile ester bond between the H and the K group, which slows degradation. Crystallinity of the polymer or copolymer can be affected by typical factors such as tacticity, molecular weight, etc.
- In an alternative structure, H can be the residue of an amino acid, especially of an alpha-amino acid. The linkage between the A and the H group is then an amide linkage. This increases the difference in hydrolysis rates between the A-H linkage and the H-K linkage when K is being removed. For example, glycine ethyl ester hydrochloride is commercially available, and could be acrylated under essentially the same conditions as methyl glycolate (above), particularly after conversion to the free amine. It is expected that it would preferentially de-esterify to form the derivatized lactic acid under the same conditions as ALM (see Example 33).
- K is an esterified group, which is methyl in ALM. The lower alcohols are preferred as sources of K groups, as they will become innocuous alcohols upon hydrolysis of the ester bond to the H group's carboxyl. These include methanol, ethanol, propanol, isopropanol, isomers of butanol, isomers of pentanol, and isomers of hexanol. More generally, larger alkyls are also suitable, such as those formed from fatty acids (containing up to about 30 carbon atoms), or from sterols (e.g., cholesterol, cholestanol) or other lipid materials with hydroxy groups (e.g., sphingosine). As is known, increase in the size of the K component will tend to increase the hydrophobicity of the material, which will change both its mechanical properties and its degradation time.
- Other K groups containing alcohol groups (to provide a readily hydrolyzable linkage) are possible. These may include biologically active molecules, polymers, and other large molecules. Steric considerations will generally require that such monomers be polymerized together with small monomers—for example, AHK molecules with K derived from lower alcohols; or suitable non-AHK polymerizable monomers.
- Some of the starting “HK” materials for the synthesis in which an activated “A” group (here, acryloyl chloride) is added to a preformed HK group (here, methyl lactate) are commercially available. These include ethyl and/or methyl esters of lactic, glycolic, 2-hydroxybutyric, 2-hydroxycaproic, and 6-hydroxycaproic acid. However, propyl and higher substituents are not readily available. The amine equivalents (e.g., glycine ethyl ester hydrochloride) have similar availability. A synthetic method for making monomers containing any of a wide range of K groups is described in the examples. The principal requirement of the “K” group is that it contain at least one hydroxyl group.
- C. Excipients
- Compositions can also include ancillary reagents, such as catalysts or initiators of polymerization; excipients, including buffers; stabilizers; and dye. The compositions will be tailored to accommodate the chemistry or chemistries that are used to polymerize and crosslink the materials.
- It should be noted that while reinforcing materials such as fibers and particulates can be added to the hydrogel materials to improve their toughness under load and shear, it is preferable if the hydrogel materials spontaneously form segregated microstructure during polymerization or subsequent hydration. Such materials are thereby “self-reinforcing”. This unusual property, when it can be obtained while satisfying other requirements, is a preferred but not required feature.
- The hydrogel materials may contain other therapeutic, prophylactic or diagnostic materials which interact with or on the tissues to which the material has been applied. These materials include drugs and other therapeutically active materials, such as proteins, small molecule drugs, nucleic acid molecules, sugars and polysaccharides, lipids, natural extracts, glycosaminoglycans and inorganic compounds. As noted above, excipients such as plasticizers, emollients, fillers, lubricants, buffers, and stabilizers, may also be added. Any of these may be admixed into the material before or during polymerization or crosslinking, and optionally may be encased in liposomes, microparticles, or other delivery forms, for local or systemic delivery.
- Any reaction chemistry that is compatible with application in an aqueous environment, and that can be conducted safely on living tissue, is potentially suitable to polymerize the gels. A preferred chemistry involves the use of ethylenically-unsaturated materials, including but not limited to vinyl, acrylic, and alkyl groups (“unsaturated group”). At least some of the macromer or the monomer is preferably substituted (,as terminal or side groups,) so as to be at least difunctional to allow crosslinking in addition to linear polymerization. Reactions with ethylenically unsaturated materials commonly are free-radical chain-growth reactions, and typically are initiated with the use of a chemical initiator or a photoinitiator. Free-radical polymerizable linkages are preferred for forming the hydrogels. The preferred monomers, DAA and ALM, react by this mechanism, and it is convenient to use the same method for crosslinking. However, polymerization and/or crosslinking can be provided by other chemistries, such as those noted above. Any crosslinking or polymerization method that can be used in situ in the body is potentially of use.
- An alternative chemistry involves step-growth (condensation) polymerization, and similar heterolytic reactions. For example, a leaving group, such as an N-hydroxy succinimide ester, is easily displaced by a nucleophilic group, such as an amine. To create linear polymers, the preponderance of reactive molecules must have a functionality of two. To create a crosslinked gel, the composition must contain reactive molecules with functionality greater than two. Because polymerization of at least one component to form a low-solubility material is thought to be involved in obtaining the preferred gel compositions, there may be several types of reactive materials in the composition.
- Systems of polymerization and crosslinking using both types of chemistry are possible. For example, one component, or a fraction of a component, could carry an electrophilic center with a good leaving group as well as an unsaturated group, while another reactive component could carry nucleophilic groups. Then the first component could polymerize by free radicals, while also becoming crosslinked by the second component. Moreover, certain reactive groups are inherently capable of undergoing several types of crosslinking. For example, a maleimide group can undergo Michael-type addition with a nucleophile such as an amine or thiol, but can also polymerize by free radical polymerization of its double bond. It can also react by hydrolysis of its strained ring, for example by reaction with an amine to form an amide.
- Hydrogels can be homo-polymers or hetero-polymers (or co-polymers), interpenetrating networks or semi-interpenetrating networks.
- The polymerized materials can be covalently or non-covalently crosslinked. Non-covalently crosslinked materials have a molecular weight after polymerization of less than 200 kDa.
- The hydrogels described herein are useful in the treatment of what may be termed “orthopedic tissues”. The medical specialty of orthopedics is concerned with the preservation, restoration and development of the form and function of the musculoskeletal system, extremities, spine and associated structures by medical, surgical and physical methods.” (Stedman's Medical Dictionary, 25th ed., Williams & Wilkins, 1996). Orthopedic tissues include bone, cartilage, and related structures, for example, meniscus, bursa, synovial membranes, and other structures of the joints, as well as tendons, ligaments, muscles and the annulus and nucleus of the vertebral disks. Tissues with similar mechanical properties such as teeth, gums, and gingival ligaments can also be treated effectively with the hydrogel materials.
- The properties of the hydrogel forming reagents have been tailored to enable the creation of materials that are hydrogels (as herein defined), and that also adhere well to orthopedic tissues. Such strong adherence can be difficult to achieve with polymeric materials in current uses. For example, fasteners and sculpting of undercuts and hollows in bone and cartilage can be required to obtain good attachment of available polymeric implants. The hydrogel materials described herein are characterized by their strong adherence. When polymerized in the presence of the tissue with the use of appropriate priming techniques, the hydrogels can adhere to tissue with sufficient tenacity that either the gel or the tissue will fail before the adhesive bond between the tissue and the implant is broken (“excellent” adherence, as defined above). “Good” adherence is also acceptable in these materials.
- Moreover, these materials have the appropriate mechanical strength and other mechanical properties, such as resilience and stiffness, to withstand the forces applied in these anatomical situations. In addition, the same physical properties make the hydrogels suitable for coating of implants applied to the joints and similar structures. Among the therapeutic benefits provided by these hydrogels is the provision of lubricity to a treated surface. The hydrogel coating can simulate the natural lubricity of an orthopedic surface, such as cartilage, thereby allowing favorable joint articulation while preventing damage as the underlying tissue heals.
- Another benefit is the ability to remodel a joint surface by shaping the polymerized deposit with a mold to create or re-create a surface profile of a tissue, such as a condyle. For example, a desired profile can be present in a transparent or highly translucent molding member. The tissue surface is primed with reactive materials as described herein, and the cavity of the mold is filled with materials to form the hydrogel. The filled mold is placed, or is subsequently applied to the tissue surface, so that the unpolymerized materials are in contact with the primed surface. Then the material is polymerized by application of light, or by waiting for polymerization of pre-mixed reactive materials (in which latter case, the mold need not be transparent or translucent). After polymerization, the mold is removed, leaving a dense, lubricious, tightly-adhering hydrogel-forming material having the appropriate profile. Alternatively, if the material is applied as a paste, or physically gels on contact with tissue (for example, because of a temperature change), then it can be shaped to a profile using a scalpel or other instrument before or after polymerization.
- Likewise, the hydrogel materials and techniques described herein can be used to resurface damaged sites. For example, the site from which cartilage grafts is taken can be irregular, and be susceptible to damage, or can damage opposing surfaces. Coating or filling the void with the hydrogel materials will prevent ancillary damage while the tissue heals. The material may optionally be designed to be removed by spontaneous degradation, or by controlled abrasion, during this process. A particular advantage of the hydrogel materials, in this and other uses, is that the improved materials can be applied by minimally invasive techniques, for example through a needle or narrow cannula, and polymerized in situ. This makes resurfacing and other operations simpler, and thus less traumatic and less costly, while improving the chances of success. Because the application procedure is simple and minimally invasive, it can be repeated as required to maintain the usefulness of a tissue—for example, a knee joint—and thereby postpone the requirement for a joint replacement or other invasive repair procedure. In such procedures, it is acceptable for the hydrogel-forming implant or surface coating to gradually abrade, as long as the resulting particles are of a size which is appropriate to cause no excessive tissue response. The material can concurrently degrade by simple or enzymatically-catalyzed hydrolysis.
- In another use, a torn area of a meniscus can be initially repaired by standard methods, which use pinning and suturing to re-appose the torn segments. A layer of the hydrogel is then applied. The firmly-adherent gel material redistributes the applied load on the meniscus during healing. Similar uses can be found in other locations in the body, such as in the spine, and in non-limb joints, such as the jaw.
- While the hydrogel materials have been described in terms of coatings on tissue or on implants, it is also possible to use these materials as extremely strong yet biocompatible medical adhesives, by coating both surfaces to be adhered with a primer and polymerizing the materials while the materials are in contact with both primed surfaces. Allowance should be made for the predictable expansion of the adhesive during its hydration to equilibrium.
- The present invention will be further understood by reference to the following non-limiting examples.
- The examples demonstrate that it is possible to make extremely strong, resilient, low-swelling hydrogels which are biocompatible and which adhere well to orthopedic tissue. The examples also show that the more successful formulations, in terms of having the desired end properties as polymerized gels, have an initial water content before polymerization ranging from 0% up to about 40% (wt/wt). The range giving the best gels was broad: successful formulations were found at 0% and at 33%, and at several concentrations in between.
- The remainder of the formulations contained polymerizable materials. Macromers having molecular weights above 500 Da (typically over 1000 Da, and as high as about 100 kDa,) constituted from 0% to about 50% of the weight The range of about 10% to about 20% was most often successful.
- The macromers used were also crosslinking agents. It is believed that the macromers serve two functions, as the crosslinker and as the hydrophilic region, and that these functions could be placed in separate molecules if required. However, the combination of the two functions in one molecule is convenient.
- Monomers, with molecular weights below 1000 Da, and more typically below about 500 Da, constituted from about 45% up to 100% of the formulation, typically in the range of about 50% to 90%, and most frequently in the range of about 60 to 80%. The most successful monomers, DAA and ALM, each have hydrophobic groups and more than one hydrophilic group. ALM has two ester bonds, while DAA has an amide and a ketone. The poorly water-soluble ALM could form gels at 100% concentration, which absorbed over 2% of water, and formed better gels when containing a hydrophilic crosslinker. In contrast, the water-soluble DAA, VC or combinations of the two, without a crosslinker, were not suitable as the sole polymerizable component.
- In general, polyacrylamide and polyacrylic acid are not suitable as major components of the gel since they are known to swell and form weak gels. It is significant that DAA is amphiphilic, having both hydrophilic and hydrophobic regions, and it is believed that a substantial proportion of the materials in the hydrogel should be amphiphilic. On the other hand, very hydrophobic monomers, such as methyl methacrylate or styrene, form rigid, non-swelling polymers. It is clear from the examples concerning pure ALM that using ALM as the sole monomer produces materials near the low end of the range for water absorption. However, addition of more hydrophilic monomers, particularly crosslinking macromers, imparts an improved degree of hydration as well as improved resiliance. Because the degree of hydrophobicity that is useful is limited, those “AHK” analogs of ALM that have relatively small hydroxy or amino acids, and relatively small ester groups, are preferred. In summary, a preferred composition includes at least about 5%, preferably about 10%, and most preferably about 20% to at least about 50%, of a monomer or macromer having substantial water solubility. Alternatively, the hydrophilicity can be provided by an amphiphilic macromer, even one of low solubility (e.g., certain poloxamers, such as Pluroric-type polymers) having a substantially water-soluble block comprising at least about 20% of the weight of the polymer.
- The compositions that are most suitable for these applications form gels that have a maximum equilibrium swelling in water of about 300%, and preferably less than 200%. Values of about 100%, or less, are more preferred. To maintain adequate toughness and tensile properties, the percent of solids in the swollen state should be at least about 20%, preferably 30%, and most preferably 40% or more. To obtain favorable combinations of these properties, a pre-swelling solids content of 40% or more of polymerizable materials is preferred, but this value is secondary to obtaining the required post-swelling values.
- The gels both before and after swelling must be resilient, for durability under dynamic conditions of use. A value of the percent elongation to failure of 100% or more is preferred, but smaller elongations, such as 25% to 50%, can be suitable, especially at high solids contents. There is no upper limit on the desirable elastic (reversible) elongation at failure. Some irreversible deformation may also occur. Tensile strength and modulus are clearly important. It is straightforward to obtain a measurement of tensile values, but not as easy to prescribe a limiting value, in part because of the non-criticality of the exact form of the stress-strain curve, in this application. In general, the preferred materials have tensile values of well over 1 MPa before hydration, and of over 0.4 MPa after hydration. Post-hydration values can clearly be lower, especially when the implant or coating is subject to compressive loading with little shear. Post-hydration values of 100-200 kPa are suitable. In some uses, tensile strengths of 20 to 50 kPA can be used.
- A macromer consisting of a 35 kiloDalton (kDa) core (manufacturer-specified molecular weight; MW about 27 kDa by GPC) of polyethylene glycol (PEG) is reacted with trimethylene carbonate, giving hydroxy-terminated molecules with an average of about two PEG segments and about 15 TMC groups per molecule. This molecule is then end-capped with acryloyl chloride to make it crosslinkable. The molecule is called 35KTA2. Details of synthesis are described in WO 98/12243 by Focal.
- A solution was prepared in water which contained by weight about 68% DAA, 15% 35KTA2, about 17% water, and materials for redox-assisted photopolymerization, including Irgacure® 651 (2,2-dimethoxy 2-phenyl acetophenone; DMAP), t-butyl hydroperoxide, and tiethylamine as electron carrier and buffer. This was accomplished by adding 3.0 g of 35kTA2 and 13.6 g of DAA to 3.4 g of water, and heating to 70° C. with stirring to complete dissolution. Then 83 microliters of 6% t-butylhydroperoxide (in water) and 30 microliters of molten DMAP were added, with stirring and heating as required for dissolution. The mixture was treated by centrifugation or standing to remove bubbles. It was either stored at minus 40° C. (dark), or used warm (45-50° C.) or at room temperature to form a hydrogel.
- This gel-forming material was polymerized by illumination with near-UV light, 350-400 nm band from a xenon source, for about 40 seconds at about 50 to 100 mW per square centimeter, to form bulk gels for testing of mechanical and other properties. When applied to tissue to test adherence, the tissue was primed with a solution prepared as follows. Ferrous gluconate (0.71 g) and 1.42 g D-fructose were dissolved in 100 mL of water. In 7.0 g of this solution, 3.0 g of a low-molecular weight macromer, 3.3 KLA2 (made from nominal 3.3 kDa PEG with an average of five lactate residues per PEG, acrylate end-capped) was dissolved. The primer was applied to the tissue surface with a brush. Priming technology is described in more detail in U.S. Pat. Nos. 5,800,373 and 5,844,016 to Hubbell, et al.; synthesis of the 35KTA2 macromers is described in WO 98/12243 by Focal; and synthesis of the 3.3KLA2 macromer is described in U.S. Pat. No. 5,410,016 to Hubbell et al., along with techniques for photopolymerization.
- The bulk properties of the “68 DAA/15 35KTA2” gels are presented in
FIG. 1 as formed, after incubation in water for 1 day at 37° C., and after 7 days at 57° C. (accelerated aging). - In Table 1, the preferred material is compared to cartilage and meniscus in mechanical properties: tensile modulus, tensile strength and elongation.
TABLE 1 Material Properties of Bovine Cartilage and Meniscus and Hydrogel Tensile Tensile Strength Elongation Modulus (MPa) (MPa) (%) Articular Cartilage 3-10 — — Meniscus 50-70 5-30 15-20 68 DAA/15 35KTA2/ 8.9 8 800 17 H2O (as formed) 1.1 2 500 (swollen ˜90%) - “Elongation (%)” is length at failure less original length, divided by original length. Tensile strength is secant modulus at maximum stress before failure. The final percent solids was about 40%. The gels scored “Excellent” on tissue adhesion, and passed the clamp (hemostat) test. The gels were turbid (white, nearly opaque) before swelling, and were opaque after swelling. Microscopic examination suggested the presence of heterogeneity in the structure, and possibly the presence of porosity.
- Additional samples of potentially suitable materials were prepared and subjected to a limited set of tests. These samples are shown in Table 2.
TABLE 2 DAA and Other Vinyl-Based Hydrogels % Vinyl Physical Physical % Solids Example Monomers2 Macromer(s) %1 Characteristics Characteristics H2O at Clamp5 No. (%)1 (%)1 H2O As Formed4 After Hydration Uptake Equil. test Adherence6, Notes 2 DAA (4.4) 35KTA2 60.6 Soft, elastic Very soft, elastic 362 6.36 Pass Cohesive (20.0) (swollen) Failure 20KTA2 (5.0) Artic Cartil 3 DAA (60.0) None 40.0 Rigid, opaque, Rigid, opaque, ˜0 ˜60.0 — — plastic (yielded) plastic 4 DAA (49.1) 35KTA2 32.7 Tough, opaque, Flexible, opaque, 139 28.1 Cohes. Fail (18.2) resilient resilient Patella 5 DAA (54.0) 3.3KL5 (10.0) 36.0 Strong, brittle Brittle 93 33.2 6 DAA (41.0) 35KTA2 27.2 — — 176 26.3 — — VOE (21.6) (10.0) 7 DAA (51.0) 35KTA2 34.0 Tough, notch Tough, opaque, 135 — — — (1.50) resistant flexible 8 DAA (68.0) 35KTA2 17.0 Stiff, opaque, Somewhat tough, 101 — — — (15.0) notch resistant opaque, flexible 9 DAA (49) 35KTA2 (18) 33 Very tough, -- — — — Cohesive opaque Failure Vertebral disk annulus 10 DAA (30) HDI7-BDO7, 40 Tough, opaque, Softened after 149 24 Pass 2 — 3.3 KA2 (30) good tear swell click resistance Fail 3 click 11 DAA (60) HDI7-BDO7, 20 Stiff, tough Stiffer than Ex 90 42 — promising 3.3KA2 (20) 10 polyurethane macromer 12 DAA (60) Tween A3 7 20 — — 184 31 — — AMPS (2) (5) 13 DAA (68) 35KTA2 (15) 17 Tough, opaque 87 44 — Soln. and Paste formulation soln. - Cohes Fail Paste mixed cohes/adhes Fail to cart, lig, bone 14 DAA (68) 35 KTA2 (15) 17 — — — — — Disk annulus, knee cartilage of pig, Cohes. Fail 15 DAA (68) 35KTA2 (15) 17 Tough, opaque — — — — 7 day sub Q implants - Gel formed in situ-benign tissue response 16 NIPAM (68) 35KTA2 (15) 19.4 Tough, opaque Low Mod., Clear 1018 6.6 Pass Extreme range of toughness. Loss on hydration 17 VC (69) 35KTA2 (26) 15 Clear, soft, Slightly hazy, 669 11.0 Fail Low exotherm elastic weakened 18 VC (26) 35KTA2 (13) (18) Very tough, Softened 184 28.9 — DAA (43) opaque 19 VI (84) 35KTA2 (16) 0 Did not solidify — — — — No water; melted at 82 deg. and cured 20 MVA (84) 35KTA2 (16) 0 Soft, elastic, Softened clear 325 19.8 — — same as last clear 21 DAA (59) 35KTA2 (11) 0 Rigid, Soft, opaque 145 40.8 Same; Cured as VC (30) translucent liquid or paste to tough product 22 DAA (70) F-88A2 (13) 17 Very rigid, Softened 51 54.8 translucent 23 DAA (70) F-127 A2 (13) 17 Clear, hard, Softened, 47 56.2 Pass tough translucent 24 VC (33) F-127 A2 (67) 0 Rubbery, clear, Softened, brittle 219 31.3 Fail Melted to mix tough 25 DAA (50) F-127 A2 (50) 0 Clear, tough Softened, clear, 155 39.2 Equivocal Melted to mix tough Pass 26 DAA (44) F-127 A2 (44) 12 Clear, tough Softened, clear, 131 38.3 Pass Tore cleanly from tough defect 27 VC (100) — — Yellow, tacky, Soft, weak, tacky — — — Very slow cure, rigid inhibited
Notes to Table 2:
1Percent of total formulation
2DAA = Diacetone acrylamide; VC = Vinyl caprolactam; VOE = Vinyloxyethanol; MVA = Methyl vinyl acrylamide; AMPS = 2, Acrylamido-2-methylpropane sulfonic acid; VP = N-vinyl pyrrolidone
3t-BHP, t-Butyl Hydroperoxide (˜250 ppm) for redox with primer
4UV cured (40 sec, ca. 100 mW/cm2; 350-400 nm), Irgacure ® 651 Photoinitiator, sometimes added as solution in where the weight of. VC is twice the weight of Irgacure ®.
5Hemostat (2 clicks) applied to specimen, cast and cured as “disk” on Petri dish (see details elsewhere) - swollen unless indicated. Pass means resisted breakthough for more than 5 sec. (preferably for at least 30 sec).
6Using 30% 3.3 KL5A2, 500 ppm ferrous gluconate; 1% fructose in water as primer. Adherence test involves inserting 20 gauge needle at base of gel and pulling up parallel to base. The ratings “E”, “M”, “F”, and “P” correspond with “excellent adherence”, “moderate adherence”, “fair adherence”, and “poor adherence”, respectively.
7BDO = 1.4-Butanediol; HDI = Hexamethylene diisocyanate; F-127 = Pluronic′ F-127 copolymer, Tween A3 = Tween′ surfactant, triacrylate; P-65 = Pluronic P-65 copolymer
8NIPAM = N-Isopropylacrylamide; VC = N-vinyl caprolactam; DAA = Diacetone acrylamide, VI = N-vinyl imidazole
9“Plu” = Pluronic F-88 or Pluronic F-127 copolymer
- Examples 2-27 demonstrate certain formulations that polymerize to produce hydrogels acceptable for orthopedic applications, as well as selected control materials.
- Example 2 shows a “classic” hydrogel which, although it contains some (4.4%) DAA, and although it adheres well to tissue, has a high swelling and low final solids concentration. It is too soft for use in a load-bearing application, because its final polymer concentration (6.36% solids) is too low.
- Example 3 shows that DAA without a crosslinker forms a plastic with a yield point, rather than a highly resilient material.
- Examples 4, 5, 7, and 9 show variations of the preferred formula, which is depicted in example 8. Like example 8, these examples also yield hydrogel materials useful for orthopedic applications.
- Example 6 shows partial substitution of DAA with a charged monomer.
- Examples 10 and 11 show the use of a polyether urethane backbone, the synthesis of which is described below in Example 28.
- Example 12 shows use of a surfactant, polyoxyethylene sorbitan monolaurate (Tween® 20), which has been derivatized to contain about three acrylic groups per molecule, as a hydrophilic crosslinking macromer.
- Examples 13 and 14 show adherence of the preferred formula of Examples 1 or 8 to various tissues. Example 13 also compares the preferred formulation as a solution (after heating) versus as a paste, as obtained without heating, or on thawing from the frozen state without heating. The paste is less adherent, giving “Moderate” rather than “Excellent” adhesion.
- Example 15 summarizes a subcutaneous implantation experiment (in rats) with the preferred formulation. Good biocompatibility (minimal tissue response) was found.
- Examples 16 and 17 show that complete substitution of N-isopropyl acrylamide (NIPAM) and vinylcaprolactam (VC) for DAA gives gels that swell extensively and thereby lose toughness. However, Example 18 shows that VC can partially substitute for DAA with retention of desirable properties. Since DAA is more hydrophobic than VC, this effect may demonstrate desirability for hydrophobicity in the material.
- Examples 19-21 show non-water-containing formulations, made by co-dissolving the macromers and the monomers with heating. Example 19 is unsuitable; Example 20 is marginal but acceptable; and Example 21 is essentially the same as Example 18, which contained water during
- Examples 4, 5, 7, and 9 show variations of the preferred formula, which is depicted in example 8. Like example 8, these examples also yield hydrogel materials useful for orthopedic applications.
- Example 6 shows partial substitution of DAA with a charged monomer.
- Examples 10 and 11 show the use of a polyether urethane backbone, the synthesis of which is described below in Example 28.
- Example 12 shows use of a surfactant, polyoxyethylene sorbitan monolaurate (Tween® 20), which has been derivatized to contain about three acrylic groups per molecule, as a hydrophilic crosslinking macromer.
- Examples 13 and 14 show adherence of the preferred formula of Examples 1 or 8 to various tissues. Example 13 also compares the preferred formulation as a solution (after heating) versus as a paste, as obtained without heating, or on thawing from the frozen state without heating. The paste is less adherent, giving “Moderate” rather than “Excellent” adhesion.
- Example 15 summarizes a subcutaneous implantation experiment (in rats) with the preferred formulation. Good biocompatibility (minimal tissue response) was found.
- Examples 16 and 17 show that complete substitution of N-isopropyl acrylamide (NIPAM) and vinylcaprolactam (VC) for DAA gives gels that swell extensively and thereby lose toughness. However, Example 18 shows that VC can partially substitute for DAA with retention of desirable properties. Since DAA is more hydrophobic than VC, this effect may demonstrate desirability for hydrophobicity in the material.
- Examples 19-21 show non-water-containing formulations, made by co-dissolving the macromers and the monomers with heating. Example 19 is unsuitable; Example 20 is marginal but acceptable; and Example 21 is essentially the same as Example 18, which contained water during polymerization. Note that Example 20 uses methyl vinylacrylamide (MVA) as monomer, and does not contain DAA.
- Examples 22-26 show various formulations in which the macromer is an acrylated poloxamer (i.e., PEG-PPO block copolymer), made by simple acrylation of commercial materials, such as the Pluronic® surfactants by BASF. These macromers, which have hydrophobic segments, can also form hydrogel materials for orthopedic use. However, the formulation with VC is relatively brittle, while the DAA-containing formulae are acceptable.
- Example 27 shows that VC alone is not satisfactory, as expected from the absence of crosslinking.
- The reaction of PEG or poloxamer diols and, optionally short-chain diols with diisocyanates, produces macromeric diols which can be reacted with acryloyl chloride, optionally after reaction to provide degradable linkages, to provide acrylic-functional macromonomers with a wide range of properties from soft and weak to quite tough. These versatile compositions allow control of solubility and hydrophobicity.
- A macromer with a polyurethane backbone, used in Examples 10 and 11 above, was prepared by reacting 1,4-butanediol (1.27 g, 0.0147 m), PET, MW 3,400 (50.00 g, 0.0147 m) and 1,6-diisocyanatohexane (4.66 g, 0.0277 m) in toluene with dibutyltin dilaurate catalyst (80° C., 4 hr.). The resulting macrodiol was acrylated with acryloyl chloride and isolated by precipitation with hexane. This material was used in an adhesive/sealant fonnulation, shown in Example 10, by mixing it (3.0 g) into a solution of DAA (3.0 g) in water (4.0 g). This solution was warmed and 6% aqueous t-butyl hydroperoxide (42 mL) along with molten Irgacure® 651 (15 μL) were mixed in. The resulting formulation was treated to remove bubbles by centrifugation or allowing it to stand at ambient and stored at −40° or used to prepare hydrogel.
- A similar preparation was used in Example 11 by mixing 2 g of the acrylated polyurethane with a solution containing 6 g of DAA and 2 g of water; the other ingredients were the same.
- An acute implant study was performed with the preferred composition DAA (68%)/35KTA2 (15%)/H2O (17%), on a rabbit medial femoral condyle in which a 3 mm×1 mm defect had been created. A strong bond was formed between the hydrogel implant and the cartilage and bone to which it had been applied.
- A 10 day study showed that the hydrogel remained in place with no apparent damage. Surrounding tissue was found to be comparable to untreated, injured controls, demonstrating short-term biocompatibility. In particular, histological sections showed no apparent damage or injury to adjacent cartilage, either in the chondrocytes or in the matrix. The materials used in this study had previously passed cytocompatibility tests and were sterile and non-pyrogenic. The results indicated that the hydrogel replaced cartilage tissue, caused no damage, and allowed function of the joint for the duration of the study.
- Acryloyllactic acid-methyl ester was designed for the formation of orthopedic materials. Acryloyllactic acid-methyl ester (ALM; methyl acryloyl lactate; the acrylic ester of lactic acid methyl ester; CH2⊚CH—C(═O)OCH(CH3)C(═O)OCH3) was prepared as follows.
- A 15.61 g amount of methyl lactate (isomer S(−)) in 81 mL toluene was reacted with 13.79 g acryloyl chloride in the presence of 15.79 g triethylamine at less than 20° C. The acryloyl chloride was added drop-wise with cooling to the reaction mixture containing the TEA, to control the exotherm. The resultant TEA.HCl salt was filtered off; and the ALM/toluene solution was purified by passing it through a column containing 15 g alumina, and stabilized with 6.5 mg hydroquinone. The ALM product was isolated by removal of toluene under vacuum using a rotary evaporator.
- The ALM yield ranged from 72% to 75%. Based on analysis by Proton-Nuclear Magnetic Resonance Spectroscopy (H-NMR), the amber product typically contains: 94.4% ALM, 1.0% acryloyllactic acid ethyl ester (ALE), 0.0% TEA.HCl, 1.43% methyl lactate, 0.72% acrylic acid, and 1.45% toluene.
- Then the ALM was distilled under vacuum at 60-62 C and 0.8-0.95 mTorr, yielding a clear, colorless fluid. Based on analysis by H-NMR, the ALM typically contains: 98.01% ALM, 0.74% ALE, 0.0% TEA.HCl, 1.43% methyl lactate, 0.22% acrylic acid, and 0.02% toluene.
- Polymer A: A neat solution of 150 g ALM was auto-polymerized under vacuum at 60-70° C. for about 20 minutes (exotherm to 120° C.). The very elastic, ultra high molecular weight (MW) polymer required breaking of the reaction vessel for removal. The polymer swelled and or showed partial solubility in most organic solvents, including chloroform, methylene chloride, dimethyl sulfoxide, tetrahydrofuran, hexafluorisopropanol, but was not soluble in water. This material hydrated 2.7% over a period of 3 days at 37° C. and had a modulus of 338.64 kPa after vacuum drying.
- Polymer B: A neat solution of 1.95 g ALM was polymerized under N2 with 10.0 mg benzoyl peroxide as initiator by heating at 60-70° C. for about 5 minutes. The elastic, high MW polymer required breaking of the reaction vessel for removal. This polymer had a modulus of 29.55 kPa.
- Polymer C: A low MW equivalent was prepared by polymerization of 2.45 g ALM with 30.2 mg benzoyl peroxide as initiator by heating at 60-70° C. for about 5 minutes. This polymer had a modulus of 16.2 kPa. Both Polymers B and C were very flexible and soluble in most organic solvents, including chloroform, methylene chloride, dimethyl sulfoxide, tetrahydrofuran, but were not soluble in water.
- A 0.2261 g piece of the high MW polyALM (Polymer B) was incubated with about 30 mL of phosphate buffer pH 7.4 at 37° C. The sample weight was 0.2272 g after 3 days. The material was dried for 24 hrs under vacuum at room temperature. The weight decreased to 0.2212 g, indicating an equilibrium hydration of about 2.2%. This demonstrates that although the high MW polyALM was insoluble in water, it absorbed water to at least 2.2% by weight. The hydrated polyALM was lubricious rather than tacky. The modulus of this incubated polymer was 44.18 kPa.
- A 0.3163 g amount of the low MW polyALM (Polymer C) was incubated with about 30 mL of phosphate buffer pH 7.4 at 37° C. The sample weight was 0.3131 g after 3 days. The material was dried for 4 hrs under vacuum at room temperature. The weight decreased to 0.2967 g, indicating an equilibrium hydration of about 5.2%. This demonstrates that although the low MW polyALM was insoluble in water, it absorbed water to at least 5.2% by weight. The hydrated polyALM was lubricious rather than tacky. The modulus of this polymer was 26.95 kPa
- Polymers A, B, and C were incubated at 85° C. in water at pH 11.8-12.5. After 8 days, Polymer A had substantially dissolved. The aqueous solution was viscous. Polymers B and C substantially dissolved over 6 days at 85° C. The aqueous solutions were somewhat viscous.
- Mechanical properties of the swollen (24 hrs) and unswollen poly ALM, Polymers A, B, and C, include:
- a) all three materials passed the forceps test for toughness; and
- b) all three materials had an extension to break of at least 100%.
- A sensory test (manipulation) indicated that the materials were both deformable, but would probably be sufficiently tough to protect cartilage.
- Thus, polymers of ALM can be prepared to have moduli, toughness and hydration appropriate for application to orthopedic tissues, and further are degradable in an accelerated test.
- ALM was copolymerized with other materials. Combinations tested included:
- a) 17% 35KTA2 macromer (see description in Table 2), 18% water and 65% ALM, mixed in that order by heating to about 70° C. This mixture was polymerized with UV light in the presence of 0.3% Irgacure® photoinitiator. The resulting material was opaque, and felt somewhat porous. After incubation with water, the material was lubricious and had apparently swelled, but it failed the forceps test.
- b) 60% ALM, 30% vinyl caprolactam (VC), and 10% 35KTA2 were mixed by heating to about 70° C. This mixture was polymerized with UV light in the presence of 0.3% ppm Irgacure® photoinitiator. The as-polymerized material was clear, but turned opaque on brief incubation with water. The material was rigid and slightly brittle before hydration, but swelled about 40% and became resilient and plastic after overnight hydration. Elongation to break was over 50%, and the material passed the forceps test for toughness. The compressive modulus of the hydrated material was 151 kPa.
- c) 75% ALM,15% VC, and 10% 35KTA2 were mixed by heating to about 70° C. This mixture was polymerized with UV light in the presence of 0.3% ppm Irgacure® photoinitiator. The as-polymerized material was clear, but turned opaque on brief incubation with water. This material was less rigid and less brittle than the material described in example b) before hydration, but this material swelled about 40% and became resilient and plastic after overnight hydration. Elongation to break was over 50%, and the material passed the forceps test for toughness. A folded hydrated disc sprang back to its original shape in less than 5 seconds, whereas an equivalent disc from material described in example b, above, required about 30 seconds to spring back.
- d) 90% ALM and 10% 35KTA2 were mixed by heating to about 70 C. This mixture did not polymerize within 5 minutes with UV light in the presence of 0.3% ppm Irgacure® photoinitiator.
- Examples 30 and 31 demonstrate that a material useful as an orthopedic repair material, as defined herein, can be made from a degradable material. Based on these examples, one of skill in the art can make a new material, which has the desired properties of low swelling at high proportions of solids, high tensile modulus, significant elongation to failure, biocompatibility, and adherence.
-
Step 1. Synthesis of ALA (Acryloyl lactic acid). The ALM material described above is a convenient starting material for this synthesis, because methyl lactate is commercially available. Acryloyl chloride can be substituted with other active ethylenically unsaturated compounds, for example acryl imidazole or methacryl bromide or cinnamoyl succinimide, depending on the active group desired in the AHK material. - ALM is hydrolyzed to ALA by selective de-esterification in basic aqueous solution. The reaction takes advantage of the more rapid hydrolysis of the methyl lactate ester (the H to K bond) compared to the acryloyl-lactyl ester (the A to H bond). in a typical procedure, 10.03 g of ALM (92.92% pure) is dispersed in 90 mL of water and hydrolyzed with 5.45 mL of 10 N sodium hydroxide to the Na-acryloyllactic acid salt. The base is added dropwise at 20-25° C. The Na-acryloyllactic acid salt is converted to acryloyllactic acid (ALA) with 6N HCl at pH 1.0. The ALA is extracted from the aqueous phase with 112 mL toluene overnight using a liquid-liquid extractor. Residual moisture is removed with 6 g of magnesium sulfate. After filtration of the magnesium sulfate, the toluene is removed under vacuum using a rotary evaporator. The concentrated ALA is a yellow colored oil. Typical analysis of ALA by 1H-NMR:
% ALA % Toluene % Lactic Acid % Acrylic Acid 95.78 2.53 0.16 1.53
It was determined experimentally that the above conditions optimized the yield of acryloyllactic acid (ALA), in that most of the ALM had hydrolyzed but significant hydrolysis of the acryloyl-lactyl ester bond had not begun. - Step 2. Synthesis of ALC (acryloyl lactoyl chloride, CH2═CH—CO—OCH—O—CH(CH3)—CO—Cl). This step is a straightforward activation reaction for a carboxylic acid, and many procedures are known for such activation.
- In a typical procedure, crude ALA (free acid) was taken up in tetrahydrofuran (THF), and an excess of oxaloyl chloride and a catalytic amount of dimethylformamide (DMF) were added. After incubation for about 20 minutes at 0° C., the reaction was essentially complete. The crude reaction mixture was used directly for the next step.
- Step 3. Synthesis of AHK esters. This is simply a reaction of an active carboxyl, such as an acyl chloride, with an alcohol. Many such procedures are known in the literature. The following hypothetical experiment illustrates the general method.
- Rather than purifying the ALC, it is most convenient and efficient to add this ALC containing solution directly to a desired alcohol in a suitable solvent along with a suitable amine (e.g. pyridine or triethylamine) to scavenge generated acid. For example, the above THF solution containing ALC can be added to a solution of 0.9% equivalent of cholesterol in toluene, based on the calculated ALA content and triethylamine. After completion of the reaction, the cholesterol ester of ALA is obtained after removal of the amine salt and concentration on a rotary evaporator under reduced pressure.
- The activation of the free acid (e.g. ALA) to the activated ester (e.g., ALC) and subsequent synthesis of an AHK ester can also be accomplished as a single or stepwise “one-pot” activation, using suitable acylating agents—for example, dicyclohexylcarbodiimide (DCC) with a catalytic amount of dimethylaninopyridine. A variety of groups can be used as leaving groups C. These include a halogen, a residue of a succinimidyl group, a residue of imidazole, a residue of a thioester, nitrophenols, pyridines, and o-acyl ureas. The key requirement is that the leaving group be readily displacable by an nucleophilic reagent, such as a hydroxyl group, an amine, or a thiol.
- Polyvinyl alcohol (PVA) was reacted with ALC to form the monomer acryloyl-lactyl-PVA. ALC was prepared essentially as described above. PVA from Aldrich had a stated molecular weight of 10 kDa (however the actual weight was from 9 kDa to 10 kDa) and was stated to be about 80% hydrolyzed. Ten grams of PVA were placed in a 3-neck 250 mL flask and pyridine was added to about 200 mL final volume. The mixture was stirred under nitrogen to dissolve the PVA. The flask was heated to about 95° C. and distillation of pyridine began. The PVA began to precipitate at about 120° C.; addition of about 200 mL of dimethylacetamide (DMAC) produced a homogenous solution and reduced the temperature to about 70° C. After reduction in volume by distillation to about 200 mL, the mixture was allowed to cool to 60° C. and ALC (450 μL; approximately 97% purity and activity) was added.
- The mixture was maintained at 60° C. under stirring and nitrogen for 20 minutes. Then it was precipitated by pouring it into 1800 mL of toluene with vigorous stirring. The gelatinous precipitate was vacuum filtered. The precipitate was mixed with 200 mL hexanes, and filtered; this was repeated twice. A fine damp powder was obtained and was vacuum dried at 40° C. overnight.
- The resulting yield contained 9.18 g. 1H-NMR analysis indicated about 0.77 acrylate-lactate substitution per PVA molecule. Free radical polymerization of this monomer failed to yield a gel, as expected from the low degree of substitution and the likelihood of steric hindrance.
- Another experiment, in which DMAC was the solvent and 300 μL of pyridine was added along with 450 μL of ALC for a 60 minute reaction time, produced a polymer at 9.2% yield. At 10% polymer in buffered water, this polymer gave a loose gel when copolymerized with about an equal weight of vinyl caprolactone. The copolymerization was carried out using eosin Y as photoinitiator and triethanolamine as electron transfer reagent under visible light.
- This study demonstrates that the monomer can include a polymer as the “K” group, and its properties can be tailored by variable degrees of derivatization.
- Modifications and variations of the hydrogels and methods for manufacture and use thereof will be obvious to those skilled in the art. Such modifications and uses thereof will be obvious to those skilled in the art.
Claims (21)
1. A covalently polymerizable, water-absorbing, hydrogel-forming material,
wherein the material has both hydrophilic and hydrophobic regions and is polymerized to form a hydrogel characterized as having the following properties:
a) absorbing water to less than about 300% of its initial weight, on equilibration with water or bodily liquids,
b) having a solids content of at least about 20% after equilibration in water or bodily liquids;
c) having an elongation to failure of at least about 25% hydration to equilibrium; and
d) being sufficiently biocompatible to permit the treatment or repair of biological tissue, or used as an implant in a patient.
2. The material of claim 1 , having a molecular weight after polymerization of at least 10 kDa.
3. The material of claim 1 , which is covalently crosslinked.
4. The material of claim 1 , which is non-covalently crosslinked.
5. The material of claim 1 , having a tensile modulus of at least about 50 kPa after equilibrium hydration.
6. The material of claim 1 , having an equilibrium water content of at least about 2%.
7. The material of claim 1 , being capable of being formed in situ on body tissue or a medical implant by one or both of polymerization and crosslinking.
8. The material of claim 1 , adhering to tissue when polymerized thereon.
9. The material of claim 1 , being substantially elastic during a 10% elongation and release therefrom.
10. The material of claim 1 , further characterized in being lubricious.
11. The material of claim 1 , further characterized in comprising, before polymerization or crosslinking,
a) at least one component which is a macromer of molecular weight of about 1000 Da or more, at least 20% of the macromer being a hydrophilic block or region and comprising at least one chemical reactive group; and
b) at least one component bearing more than one chemically reactive group.
12. The material of claim 1 , further characterized in comprising, before polymerization or crosslinking, at least 20% by weight of at lest one amphiphilic water-soluble monomer of molecular weight less than about 100 Da.
13. The material of claim 1 , in which the water absorption at equilibrium hydration is less than about 200%.
14. The material of claim 1 , in which the solids content is at least about 25% after equilibrium swelling.
15. The material of claim 1 , in which the elongation to failure is at least about 200%.
16. The material of claim 1 , in which the tensile modulus is at least 200 kPa.
17. The material of claim 1 , further compromising a therapeutic, prophylactic or diagnostic agent.
18. The material of claim 1 formed by polymerization of a mixture comprising:
a) about 40% to about 100% by weight of one or more polymerizable monomers having a molecular weight of about 1000 Da or less;
wherein at lest about 40% by weight of the monomers consists of amphiphilic monomers;
wherein no more than about 50% by weight of the monomers consists of functionally hydrophobic monomers;
b) 0% to about 40% by weight of a reactive macromer having a molecular weight greater than about 500 Da, which comprises on average more than one polymerizable group per molecule, and which has hydrophilic groups comprising about 20% of the macromer; and
c) 0% to about 40% water.
19. The material of claim 1 in the form of a coating on an implant device.
20. The material of claim 1 forming an implant or device.
21-37. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/301,055 US20060093648A1 (en) | 1999-09-10 | 2005-12-12 | Hydrogels for orthopedic repair |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15319099P | 1999-09-10 | 1999-09-10 | |
US09/658,390 US7008635B1 (en) | 1999-09-10 | 2000-09-08 | Hydrogels for orthopedic repair |
US11/301,055 US20060093648A1 (en) | 1999-09-10 | 2005-12-12 | Hydrogels for orthopedic repair |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/658,390 Continuation US7008635B1 (en) | 1999-09-10 | 2000-09-08 | Hydrogels for orthopedic repair |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060093648A1 true US20060093648A1 (en) | 2006-05-04 |
Family
ID=35966190
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/658,390 Expired - Lifetime US7008635B1 (en) | 1999-09-10 | 2000-09-08 | Hydrogels for orthopedic repair |
US11/301,055 Abandoned US20060093648A1 (en) | 1999-09-10 | 2005-12-12 | Hydrogels for orthopedic repair |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/658,390 Expired - Lifetime US7008635B1 (en) | 1999-09-10 | 2000-09-08 | Hydrogels for orthopedic repair |
Country Status (1)
Country | Link |
---|---|
US (2) | US7008635B1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060210594A1 (en) * | 2005-03-15 | 2006-09-21 | Sdgi Holdings, Inc. | Composite spinal nucleus implant with water absorption and swelling capabilities |
US20080021563A1 (en) * | 2006-06-23 | 2008-01-24 | Surmodics, Inc. | Hydrogel-based joint repair system and method |
WO2008058233A2 (en) * | 2006-11-08 | 2008-05-15 | Maastricht University | In vivo bioreactors and methods of making and using same |
US20080220047A1 (en) * | 2007-03-05 | 2008-09-11 | Sawhney Amarpreet S | Low-swelling biocompatible hydrogels |
WO2009073205A1 (en) * | 2007-12-07 | 2009-06-11 | Biocure, Inc. | Bone substitute |
US20090182425A1 (en) * | 2007-12-04 | 2009-07-16 | Charite - Universitatsmedizin Berlin | Sheet or Tubular Structure Consisting of Elastic Biocompatible Material and its Use |
US20090226531A1 (en) * | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
WO2011025650A1 (en) * | 2009-08-25 | 2011-03-03 | Genzyme Corporation | Cartilage repair |
US20120232657A1 (en) * | 2004-10-05 | 2012-09-13 | David Myung | Hydrogel Arthroplasty Device |
US10752768B2 (en) | 2008-07-07 | 2020-08-25 | Hyalex Orthopaedics, Inc. | Orthopedic implants having gradient polymer alloys |
US10792392B2 (en) | 2018-07-17 | 2020-10-06 | Hyalex Orthopedics, Inc. | Ionic polymer compositions |
US11015016B2 (en) | 2011-10-03 | 2021-05-25 | Hyalex Orthopaedics, Inc. | Polymeric adhesive for anchoring compliant materials to another surface |
US11077228B2 (en) | 2015-08-10 | 2021-08-03 | Hyalex Orthopaedics, Inc. | Interpenetrating polymer networks |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008396A1 (en) * | 1999-03-17 | 2003-01-09 | Ku David N. | Poly(vinyl alcohol) hydrogel |
US7959636B2 (en) * | 2002-08-15 | 2011-06-14 | Arthrex, Inc. | Osteochondral repair using plug fashioned from whole distal femur or condyle formed of hydrogel composition |
AU2003268167B2 (en) * | 2002-08-20 | 2009-10-22 | Exactech, Inc. | Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition |
CA2513502C (en) * | 2003-01-16 | 2012-02-07 | Chih-Chang Chu | Partially biodegradable temperature and ph sensitive hydrogel |
US7279174B2 (en) * | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
NL1023926C2 (en) * | 2003-07-15 | 2005-01-18 | Univ Groningen | Prosthesis based on a fiber-reinforced hydrogel and method for manufacturing the prosthesis and its application. |
WO2005077013A2 (en) * | 2004-02-06 | 2005-08-25 | Georgia Tech Research Corporation | Surface directed cellular attachment |
CA2558661C (en) * | 2004-02-06 | 2012-09-04 | Georgia Tech Research Corporation | Load bearing biocompatible device |
US20050278025A1 (en) * | 2004-06-10 | 2005-12-15 | Salumedica Llc | Meniscus prosthesis |
JP4857268B2 (en) * | 2004-06-29 | 2012-01-18 | バイオキュア・インコーポレーテッド | Spinal disc nucleus pulposus graft |
US20070118218A1 (en) * | 2005-11-22 | 2007-05-24 | Hooper David M | Facet joint implant and procedure |
US20070149641A1 (en) * | 2005-12-28 | 2007-06-28 | Goupil Dennis W | Injectable bone cement |
WO2008130529A1 (en) * | 2007-04-16 | 2008-10-30 | University Of Toledo | Hybrid biomimetic particles, methods of making same and uses therefor |
US20080269897A1 (en) * | 2007-04-26 | 2008-10-30 | Abhijeet Joshi | Implantable device and methods for repairing articulating joints for using the same |
US20080268056A1 (en) * | 2007-04-26 | 2008-10-30 | Abhijeet Joshi | Injectable copolymer hydrogel useful for repairing vertebral compression fractures |
US20090010990A1 (en) * | 2007-06-20 | 2009-01-08 | Little Marisa A | Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process |
CA2718718A1 (en) * | 2008-03-21 | 2009-09-24 | Biomimedica, Inc | Methods, devices and compositions for adhering hydrated polymer implants to bone |
GB0807154D0 (en) * | 2008-04-18 | 2008-05-21 | Univ Aston | Intervertebral disc |
US20090297603A1 (en) * | 2008-05-29 | 2009-12-03 | Abhijeet Joshi | Interspinous dynamic stabilization system with anisotropic hydrogels |
US7932305B2 (en) * | 2008-06-27 | 2011-04-26 | Ethicon, Inc. | Viscous α-cyanoacrylate compositions |
US8883915B2 (en) | 2008-07-07 | 2014-11-11 | Biomimedica, Inc. | Hydrophobic and hydrophilic interpenetrating polymer networks derived from hydrophobic polymers and methods of preparing the same |
EP2297217B1 (en) * | 2008-07-07 | 2021-10-20 | Hyalex Orthopaedics, Inc. | Hydrophilic interpenetrating polymer networks derived from hydrophobic polymers |
WO2010017282A1 (en) | 2008-08-05 | 2010-02-11 | Biomimedica, Inc. | Polyurethane-grafted hydrogels |
WO2010027349A1 (en) * | 2008-09-03 | 2010-03-11 | Transdermal Innovations Inc. | Multipurpose hydrogel compositions and products |
WO2011068846A2 (en) | 2009-12-01 | 2011-06-09 | Bridgestone Corporation | Modified rubber compositions and methods of preparation |
EP2512354A4 (en) * | 2009-12-18 | 2015-09-09 | Biomimedica Inc | Method, device, and system for shaving and shaping of a joint |
US8835395B2 (en) | 2010-03-10 | 2014-09-16 | Kansas State University Research Foundation | Protein peptide hydrogels |
EP2757964B1 (en) | 2011-05-26 | 2016-05-04 | Cartiva, Inc. | Tapered joint implant and related tools |
WO2012162637A2 (en) | 2011-05-26 | 2012-11-29 | Kansas State University Research Foundation | Vaccine adjuvants from self-assembling peptides |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
EP2782524B1 (en) | 2011-11-21 | 2017-12-20 | Biomimedica, Inc | Systems for anchoring orthopaedic implants to bone |
US10350072B2 (en) | 2012-05-24 | 2019-07-16 | Cartiva, Inc. | Tooling for creating tapered opening in tissue and related methods |
US20140178988A1 (en) * | 2012-10-08 | 2014-06-26 | Biotime, Inc. | Differentiated Progeny of Clonal Progenitor Cell Lines |
WO2016161025A1 (en) | 2015-03-31 | 2016-10-06 | Cartiva, Inc. | Hydrogel implants with porous materials and methods |
EP3892241A1 (en) | 2015-03-31 | 2021-10-13 | Cartiva, Inc. | Drill bit for carpometacarpal implant |
CN114736397B (en) * | 2022-04-13 | 2023-01-13 | 中山大学附属第八医院(深圳福田) | Preparation method and application of wet adhesive hydrogel for dura mater injury repair |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057535A (en) * | 1976-04-14 | 1977-11-08 | Tatyana Esperovna Lipatova | Adhesive for gluing together soft body tissues |
US4511478A (en) * | 1983-11-10 | 1985-04-16 | Genetic Systems Corporation | Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides |
US4740534A (en) * | 1985-08-30 | 1988-04-26 | Sanyo Chemical Industries, Ltd. | Surgical adhesive |
US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
US4804691A (en) * | 1987-08-28 | 1989-02-14 | Richards Medical Company | Method for making a biodegradable adhesive for soft living tissue |
US4826945A (en) * | 1987-06-09 | 1989-05-02 | Yissum Research Development Company | Biodegradable polymeric materials based on polyether glycols, processes for the preparation thereof and surgical articles made therefrom |
US4839345A (en) * | 1985-03-09 | 1989-06-13 | Nippon Oil And Fats Co., Ltd. | Hydrated adhesive gel and method for preparing the same |
US4938763A (en) * | 1988-10-03 | 1990-07-03 | Dunn Richard L | Biodegradable in-situ forming implants and methods of producing the same |
US4944542A (en) * | 1987-10-07 | 1990-07-31 | Tel Yamanashi Limited | Support device |
US4994542A (en) * | 1988-03-07 | 1991-02-19 | Asahi Glass Co., Ltd. | Surgical adhesive |
US5100992A (en) * | 1989-05-04 | 1992-03-31 | Biomedical Polymers International, Ltd. | Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5160745A (en) * | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
US5173301A (en) * | 1990-11-27 | 1992-12-22 | Sanyo Chemical Industries, Ltd. | Surgical adhesive |
US5173535A (en) * | 1988-02-11 | 1992-12-22 | Dow Corning Corporation | Plastics containing sustained release of functional materials |
US5198507A (en) * | 1990-06-12 | 1993-03-30 | Rutgers, The State University Of New Jersey | Synthesis of amino acid-derived bioerodible polymers |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5514379A (en) * | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5583114A (en) * | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5652662A (en) * | 1994-03-14 | 1997-07-29 | Mita Industrial Co., Ltd. | Communications apparatus wherein transmission of ciphered data is dependent upon available memory |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5700873A (en) * | 1995-03-07 | 1997-12-23 | Adhesives Research, Inc. | Method of preparation of water-soluble copolymer |
US5726250A (en) * | 1994-07-11 | 1998-03-10 | Adhesives Research, Inc. | Covalently crosslinked water-absorbent graft copolymer |
US5739208A (en) * | 1993-11-12 | 1998-04-14 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5744545A (en) * | 1988-11-21 | 1998-04-28 | Collagen Corporation | Biocompatible adhesive compositions |
US5800373A (en) * | 1995-03-23 | 1998-09-01 | Focal, Inc. | Initiator priming for improved adherence of gels to substrates |
US5832959A (en) * | 1995-10-16 | 1998-11-10 | Becton Dickinson Infusion Therapy Ab | Stopcocks |
US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
US5874500A (en) * | 1995-12-18 | 1999-02-23 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US5900245A (en) * | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996029370A2 (en) | 1995-03-23 | 1996-09-26 | Focal, Inc. | Redox and photoinitiator systems for priming for improved adherence of gels to substrates |
DE69721265T2 (en) | 1996-07-01 | 2004-05-06 | Universiteit Utrecht | HYDROLYZABLE HYDROGELS FOR CONTROLLED RELEASE |
US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
JP4803853B2 (en) | 1996-09-23 | 2011-10-26 | ジェンザイム・コーポレーション | Polymerizable biodegradable polymers containing carbonate or dioxanone linkages |
US6153211A (en) | 1997-07-18 | 2000-11-28 | Infimed, Inc. | Biodegradable macromers for the controlled release of biologically active substances |
ZA987019B (en) | 1997-08-06 | 1999-06-04 | Focal Inc | Hemostatic tissue sealants |
-
2000
- 2000-09-08 US US09/658,390 patent/US7008635B1/en not_active Expired - Lifetime
-
2005
- 2005-12-12 US US11/301,055 patent/US20060093648A1/en not_active Abandoned
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057535A (en) * | 1976-04-14 | 1977-11-08 | Tatyana Esperovna Lipatova | Adhesive for gluing together soft body tissues |
US4511478A (en) * | 1983-11-10 | 1985-04-16 | Genetic Systems Corporation | Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides |
US4839345A (en) * | 1985-03-09 | 1989-06-13 | Nippon Oil And Fats Co., Ltd. | Hydrated adhesive gel and method for preparing the same |
US4740534A (en) * | 1985-08-30 | 1988-04-26 | Sanyo Chemical Industries, Ltd. | Surgical adhesive |
US4806614A (en) * | 1985-08-30 | 1989-02-21 | Sanyo Chemical Industries, Ltd. | Surgical adhesive |
US5160745A (en) * | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
US4826945A (en) * | 1987-06-09 | 1989-05-02 | Yissum Research Development Company | Biodegradable polymeric materials based on polyether glycols, processes for the preparation thereof and surgical articles made therefrom |
US4804691A (en) * | 1987-08-28 | 1989-02-14 | Richards Medical Company | Method for making a biodegradable adhesive for soft living tissue |
US4944542A (en) * | 1987-10-07 | 1990-07-31 | Tel Yamanashi Limited | Support device |
US5173535A (en) * | 1988-02-11 | 1992-12-22 | Dow Corning Corporation | Plastics containing sustained release of functional materials |
US4994542A (en) * | 1988-03-07 | 1991-02-19 | Asahi Glass Co., Ltd. | Surgical adhesive |
US4938763A (en) * | 1988-10-03 | 1990-07-03 | Dunn Richard L | Biodegradable in-situ forming implants and methods of producing the same |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5744545A (en) * | 1988-11-21 | 1998-04-28 | Collagen Corporation | Biocompatible adhesive compositions |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5100992A (en) * | 1989-05-04 | 1992-03-31 | Biomedical Polymers International, Ltd. | Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5198507A (en) * | 1990-06-12 | 1993-03-30 | Rutgers, The State University Of New Jersey | Synthesis of amino acid-derived bioerodible polymers |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5173301A (en) * | 1990-11-27 | 1992-12-22 | Sanyo Chemical Industries, Ltd. | Surgical adhesive |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5514379A (en) * | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
US5739208A (en) * | 1993-11-12 | 1998-04-14 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5652662A (en) * | 1994-03-14 | 1997-07-29 | Mita Industrial Co., Ltd. | Communications apparatus wherein transmission of ciphered data is dependent upon available memory |
US5726250A (en) * | 1994-07-11 | 1998-03-10 | Adhesives Research, Inc. | Covalently crosslinked water-absorbent graft copolymer |
US5583114A (en) * | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US5700873A (en) * | 1995-03-07 | 1997-12-23 | Adhesives Research, Inc. | Method of preparation of water-soluble copolymer |
US5800373A (en) * | 1995-03-23 | 1998-09-01 | Focal, Inc. | Initiator priming for improved adherence of gels to substrates |
US5844016A (en) * | 1995-03-23 | 1998-12-01 | Focal, Inc. | Redox and photoinitiator priming for improved adherence of gels to substrates |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5832959A (en) * | 1995-10-16 | 1998-11-10 | Becton Dickinson Infusion Therapy Ab | Stopcocks |
US5874500A (en) * | 1995-12-18 | 1999-02-23 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US5900245A (en) * | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8679190B2 (en) * | 2004-10-05 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogel arthroplasty device |
US20120232657A1 (en) * | 2004-10-05 | 2012-09-13 | David Myung | Hydrogel Arthroplasty Device |
US20060210594A1 (en) * | 2005-03-15 | 2006-09-21 | Sdgi Holdings, Inc. | Composite spinal nucleus implant with water absorption and swelling capabilities |
US7857856B2 (en) * | 2005-03-15 | 2010-12-28 | Warsaw Ortho Pedic, Inc. | Composite spinal nucleus implant with water absorption and swelling capabilities |
US20080021563A1 (en) * | 2006-06-23 | 2008-01-24 | Surmodics, Inc. | Hydrogel-based joint repair system and method |
US8242179B2 (en) | 2006-06-23 | 2012-08-14 | Surmodics, Inc. | Hydrogel-based joint repair system and method |
US20120078229A1 (en) * | 2006-11-08 | 2012-03-29 | Emans Pieter J | In vivo bioreactors and methods of making and using same |
WO2008058233A2 (en) * | 2006-11-08 | 2008-05-15 | Maastricht University | In vivo bioreactors and methods of making and using same |
WO2008058233A3 (en) * | 2006-11-08 | 2008-07-24 | Maastricht University | In vivo bioreactors and methods of making and using same |
US20080241250A1 (en) * | 2006-11-08 | 2008-10-02 | Emans Pieter J | In vivo bioreactors and methods of making and using same |
US20080220047A1 (en) * | 2007-03-05 | 2008-09-11 | Sawhney Amarpreet S | Low-swelling biocompatible hydrogels |
US20090182425A1 (en) * | 2007-12-04 | 2009-07-16 | Charite - Universitatsmedizin Berlin | Sheet or Tubular Structure Consisting of Elastic Biocompatible Material and its Use |
WO2009073205A1 (en) * | 2007-12-07 | 2009-06-11 | Biocure, Inc. | Bone substitute |
US20090149954A1 (en) * | 2007-12-07 | 2009-06-11 | Xianbo Hu | Bone substitute |
US20090226531A1 (en) * | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
US10752768B2 (en) | 2008-07-07 | 2020-08-25 | Hyalex Orthopaedics, Inc. | Orthopedic implants having gradient polymer alloys |
WO2011025650A1 (en) * | 2009-08-25 | 2011-03-03 | Genzyme Corporation | Cartilage repair |
CN102596112A (en) * | 2009-08-25 | 2012-07-18 | 根茨美公司 | Cartilage repair |
US11760830B2 (en) | 2011-10-03 | 2023-09-19 | Hyalex Orthopaedics, Inc. | Polymeric adhesive for anchoring compliant materials to another surface |
US11015016B2 (en) | 2011-10-03 | 2021-05-25 | Hyalex Orthopaedics, Inc. | Polymeric adhesive for anchoring compliant materials to another surface |
US11077228B2 (en) | 2015-08-10 | 2021-08-03 | Hyalex Orthopaedics, Inc. | Interpenetrating polymer networks |
US10869950B2 (en) | 2018-07-17 | 2020-12-22 | Hyalex Orthopaedics, Inc. | Ionic polymer compositions |
US11110200B2 (en) | 2018-07-17 | 2021-09-07 | Hyalex Orthopaedics, Inc. | Ionic polymer compositions |
US11364322B2 (en) | 2018-07-17 | 2022-06-21 | Hyalex Orthopaedics, Inc. | Ionic polymer compositions |
US10792392B2 (en) | 2018-07-17 | 2020-10-06 | Hyalex Orthopedics, Inc. | Ionic polymer compositions |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Also Published As
Publication number | Publication date |
---|---|
US7008635B1 (en) | 2006-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7008635B1 (en) | Hydrogels for orthopedic repair | |
EP1231950B1 (en) | Hydrogels for orthopedic repair | |
US11015016B2 (en) | Polymeric adhesive for anchoring compliant materials to another surface | |
JP4368339B2 (en) | Compositions forming interpenetrating polymer networks for use as high strength medical sealants | |
JP5658114B2 (en) | Polymerizable emulsions for tissue engineering | |
AU2002363343B2 (en) | Synthetic matrix for controlled cell ingrowth and tissue regeneration | |
AU728281B2 (en) | Polymerizable biodegradable polymers including carbonate or dioxanone linkages | |
JP2007177244A (en) | Perfluorocyclobutane crosslinked hydrogel | |
CA2430130A1 (en) | Polyalkylene glycol viscosity-enhancing polymeric formulations | |
US20170354756A1 (en) | Polyphosphate hydrogels and methods of making and using thereof | |
WO2014138628A1 (en) | Bioadhesive hydrogel | |
Berg et al. | Biodegradable (meth) acrylate-based adhesives for surgical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENZYME CORPORATION, MASSACHUSETTS Free format text: MERGER;ASSIGNOR:FOCAL, INC.;REEL/FRAME:017295/0729 Effective date: 20040312 Owner name: FOCAL, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COURY, ARTHUR J.;GOODRICH, STEPHEN D.;KRAMER, HILDEGARD M.;AND OTHERS;REEL/FRAME:017295/0746;SIGNING DATES FROM 20001005 TO 20051016 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |